

## Minireview

# An Updated Review on Implications of Autophagy and Apoptosis in Tumorigenesis: Possible Alterations in Autophagy through Engineered Nanomaterials and Their Importance in Cancer Therapy

Habib Ghaznavi,<sup>1</sup> Milad Shirvaliloo, Amir Zarebkohan, Zinat Shams, Fatemeh Radnia, Zahra Bahmanpour, Saman Sargazi, Ramin Saravani, Sakine Shirvalilou, Omolbanin Shahraki,<sup>1</sup> Sheida Shahraki, Ziba Nazarlou, and Roghayeh Sheervalilou

*Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran (H.G.), Infectious and Tropical Diseases Research Center, (M.S.), Department of Medical Nanotechnology, School of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran (A.Z.), Department of Biological Science, Kharazmi University, Tehran, Iran (Z.S.), Department of Medical Biotechnology, Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran (F.R.), Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran (Z.B.), Cellular and Molecular Research Center, Resistant Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran (S.Sar), Cellular and Molecular Research Center, Resistant Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran (R.S.), Finetech in Medicine Research Center, Iran University of Medical Sciences, Tehran, Iran (S.Sh), Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran (O.S), Cellular and Molecular Research Center, Resistant Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran (S.Sha), Material Engineering Department, College of Science Koç University, Istanbul 34450, Turkey (Z.N.), <sup>1</sup>Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran (R.Sh)*

Received January 7, 2021; accepted April 19, 2021

## ABSTRACT

Most commonly recognized as a catabolic pathway, autophagy is a perplexing mechanism through which a living cell can free itself of excess cytoplasmic components, i.e., organelles, by means of certain membranous vesicles or lysosomes filled with degrading enzymes. Upon exposure to external insult or internal stimuli, the cell might opt to activate such a pathway, through which it can gain control over the maintenance of intracellular components and thus sustain homeostasis by intercepting the formation of unnecessary structures or eliminating the already present dysfunctional or inutile organelles. Despite such appropriateness, autophagy might also be considered a frailty for the cell, as it has been said to have a rather

complicated role in tumorigenesis. A merit in the early stages of tumor formation, autophagy appears to be salutary because of its tumor-suppressing effects. In fact, several investigations on tumorigenesis have reported diminished levels of autophagic activity in tumor cells, which might result in transition to malignancy. On the contrary, autophagy has been suggested to be a seemingly favorable mechanism to progressed malignancies, as it contributes to survival of such cells. Based on the recent literature, this mechanism might also be activated upon the entry of engineered nanomaterials inside a cell, supposedly protecting the host from foreign materials. Accordingly, there is a good chance that therapeutic interventions for modulating autophagy in malignant cells using nanoparticles may sensitize cancerous cells to certain treatment modalities, e.g., radiotherapy. In this review, we will discuss the signaling pathways involved in autophagy and the significance of the mechanism itself in apoptosis and tumorigenesis while shedding light on possible

<sup>1</sup>H.G., O.S., and R.S. contributed equally.

This work was supported by the Zahedan University of Medical Sciences [IR.ZAUMS.REC.1399.437].

The authors declare that they have no conflict of interest.  
<https://doi.org/10.1124/molpharm.121.000234>.

**ABBREVIATIONS:** Akt, protein kinase B; ARH1, aplysia ras homolog 1; ATG, autophagy-related gene; Bak1, Bcl2 antagonist killer; Bax, BCL2 associated X; Bcl2, B-cell lymphoma 2; beclin 1, a mammalian homolog of yeast Atg6 encoded by the BECN1 gene; Bid, BH3 interacting domain death agonist; Bif-1, Bax-interacting factor 1; Chemo-PTT, chemotherapy with photothermal therapy; CNT, carbon nanotube; CQ, chloroquine; CVT, cytoplasm vacuole targeting; DRAM, damage-regulated autophagy modulator; EGFR, epidermal growth factor receptor; EMT, epithelial-to-mesenchymal transition; ER, endoplasmic reticulum; GCMSNs, GNPs-capped mesoporous silica nanoparticle; HER2, human epidermal growth factor receptor 2; IFN, interferon; IONP, iron oxide nanoparticle; LC3, microtubule-associated protein light chain 3; 3-MA, 3-methyladenine; miRNA, micro RNA; MDR, multidrug resistance; MSN, mesoporous silica nanoparticle; mTOR, mammalian target of rapamycin; ND, nanodiamond; NM, nanomaterial; NP, nanoparticle; PERK, protein endoplasmic reticulum kinase; PI3K, phosphatidylinositol 3-kinase; PLGA, poly(lactic-coglycolic acid); PTT, photothermal therapy; QD, quantum dot; ROS, reactive oxygen species; TNF, tumor necrosis factor; Tor, target of rapamycin; TRAIL, TNF-related apoptosis-inducing ligand; ZnO NP, Zinc oxide nanoparticle.

alterations in autophagy through engineered nanomaterials and their potential therapeutic applications in cancer.

## SIGNIFICANCE STATEMENT

Autophagy has been said to have a complicated role in tumorigenesis. In the early stages of tumor formation, autophagy appears to be salutary because of its tumor-

suppressing effects. On the contrary, autophagy has been suggested to be a favorable mechanism to progressed malignancies. This mechanism might be affected upon the entry of nanomaterials inside a cell. Accordingly, therapeutic interventions for modulating autophagy using nanoparticles may sensitize cancerous cells to certain therapies.

## Introduction

Several types of cell death determine the ultimate fate of a living organism. This phenomenon is an integral part of life, as it maintains homeostasis by exterminating redundant cells that may otherwise become a liability. Through the never-ending course of evolution, various mechanisms of cell death have emerged, including apoptosis, necroptosis, and autophagy-dependent cell death (Kang et al., 2011; Su et al., 2015).

A self-digestive process, type II or autophagic cell death (Gozuacik and Kimchi, 2004) is one such mechanism that regulates lysosomal degradation of superfluous or erroneous materials, e.g., damaged organelles and misfolded proteins (Choi, 2012). Accordingly, autophagy is a regulatory process in which cytoplasmic vesicles with multiple membranes appear inside a cell and start engulfing bulks of cytoplasmic organelles only to disintegrate them from the cell. These so-called autophagic bodies are subsequently degraded by the lysosomal system of the very same cell. It is believed that autophagy is fundamentally different from the ordinary turnover cycle of organelles, as it assumes a broader scope in maintenance of cellular activity in conditions that, if not counteracted, might render the organism susceptible. During this process, the cell simply cannibalizes itself from the inside (Gozuacik and Kimchi, 2004). On a basal level, autophagy contributes to maintaining homeostasis by mediating the turnover of proteins and organelles; however, it can be accelerated in response to stress as a survival mechanism (Choi 2012). Based on the molecular pathways associated with the biogenesis of autophagic vesicles or autophagosomes, autophagy can be classified as canonical or noncanonical. In this regard, autophagy-related or ATG genes are also categorized into two eponymous classes, of which more than 30 members have been discovered (Rebecca and Amaravadi, 2016).

Once presumed to be a survival mechanism in yeasts under starvation, autophagy has now been recognized as a universal process involved in many cell types, particularly mammalian, that plays a major part in cellular function (Zhang et al., 2009). In fact, the phenomenon is so crucial that, if defected, certain ailments may arise as a consequence, e.g., infection, aging, neurodegeneration, myopathy, Crohn disease, and malignancies (Levine and Kroemer, 2008). In spite of all the controversies around the footprint of autophagy in malignancy, it appears that the mechanism assumes an ambivalent approach in development of tumors, as despite being a tumor-suppressive process, autophagy might contribute to the survival of malignant cells (Rosenfeldt and Ryan, 2009). Besides, tumor cells can exploit autophagy to gain resistance against several antitumor agents (Chen and Karantza-Wadsworth, 2009). Because of their rapid proliferation and altered metabolism, cancer cells are subject to more stress and have higher metabolic demands (White and DiPaola, 2009), which might

render them more dependent on autophagy as a survival mechanism (Amaravadi et al., 2011).

Recently, several studies have reported certain correlations between autophagy and nanotechnological interventions. Pieces of evidence have recently suggested the significance of autophagy in development of adaptive reactions to nanomaterials. However, the nature of such reactions is yet to be elucidated, as they often happen to vary with physicochemical properties of nanomaterials that become taken up by the cells to which they are introduced. In this regard, it can be asserted that autophagy grants the cell with cytoprotective effects in response to the uptake of foreign materials, which in this case are nanomaterials (Popp and Segatori, 2015).

Nanoparticles (NPs) are now recognized as novel materials with a capacity to induce autophagy (Zhang et al., 2009). Different NPs, such as quantum dots (QDs), nanowires, and the more recently studied rare earth oxides, can reportedly induce autophagy in cells derived from different tissues, e.g., mesenchymal stem cells, cervical cancer cells, etc. (Stern et al., 2008; Zhang et al., 2010b). QDs were first documented to exert size-dependent autophagy-inducing effects on human mesenchymal stem cells in 1999 (Seleverstov et al., 2006). It was only a decade later that an investigation on QDs with different core materials revealed that these particles were able to induce autophagy in porcine kidney cells, further supporting the theory that autophagy might be a common cellular response to nanomaterials. Interestingly, the effects of cellular stress on autophagy are determined by cell type and the kind of stimuli (Stern et al., 2008). Another study in 2011 implicated that iron oxide NPs could be used for treatment of tumors, as they had the potential to mediate autophagy in malignant cells (Khan et al., 2012).

A well founded understanding of mechanisms involved in the regulation of autophagy in malignancy and their response to nanomaterials might open a new pathway toward developing novel therapeutic interventions that can modulate this pathway either directly or indirectly. The present article will discuss the most recent advancements in understanding of autophagy in malignancy and the potential regulatory role of NPs in it.

## Autophagy: Involved Pathways

Autophagy, also known as type II cell death (Gozuacik and Kimchi, 2004), is a conserved catabolic process that can be considered as one of the main degradative pathways of unnecessary or dysfunctional cellular components, old or misfolded proteins, and superfluous or defected organelles in eukaryotic organisms (Kondo and Kondo, 2006). Besides, autophagy has a crucial role in eliminating pathogens and engulfing apoptotic cells (Mathew et al., 2007). Microautophagy, macroautophagy, and chaperone-mediated autophagy are three known types of autophagy, of which macroautophagy is the primary type that


occurs most frequently in eukaryotic cells (Li et al., 2017). In *Saccharomyces cerevisiae*, overlapping Atg genes, including Apg, Aut, and Cvt, have been found to be involved in the autophagic pathway (Gozuacik and Kimchi, 2004). Factors such as nutrient deprivation, reactive oxygen species (ROS), hypoxia, drug stimuli, aggregated proteins, and damaged organelles mainly induce autophagy, causing cells to degrade macromolecules, including proteins, lipids, and carbohydrates, to synthesize essential cell components (Choi et al., 2013; Mei et al., 2014).

Basal autophagy brings about protein degradation and organelle turnover and is a vital factor in intracellular quality control and sustaining homeostasis. At the same time, it has been revealed that autophagy is also triggered in stressful conditions to maintain cell survival (Choi, 2012). Upon receiving the signal from the cell, a cascade of reactions occur that result in the surrounding of cytoplasmic constituents by intracellular double-membraned

structures to form the autophagosomes (Levine, 2007; Zhang et al., 2009).

At first, cytoplasmic constituents are enwrapped by a membrane sac to form vesicles (Gozuacik and Kimchi, 2004). These vesicles subsequently fuse with lysosomes. After the release of lysosomal digestive enzymes into the lumen of the resulting autolysosomes, the internal contents are digested by lysosomal hydrolases. The degradation products are then recycled back to the cytosol and reused by the cell to maintain energetic homeostasis and viability (Levine, 2007; Zhang et al., 2009).

In normal cells and tissues, autophagy plays a complex and tissue-dependent role (Mizushima and Komatsu, 2011). As a cellular housekeeper, autophagy maintains homeostasis by eliminating inessential proteins and nonfunctional organelles in normal physiologic conditions (Mathew et al., 2009; Anding and Baehrecke, 2017). In this regard, aberrant regulation of autophagy can lead to severe conditions, including



**Fig. 1.** Mechanisms involved in autophagy. Stressors such as starvation and infection can induce autophagy. Upon nutrient deficiency in the environment, autophagy is usually triggered in *S. cerevisiae* to provide the prerequisite amino acids and macromolecules for the survival of the microorganism. A nutrient sensor, TOR protein kinase, is the primary molecule responsible for the regulation of autophagy inside the cell, which has been mostly investigated in fungal cells, particularly yeasts (Gozuacik and Kimchi, 2004). When nutrients are amply available, TOR protein kinase prompts phosphorylation of Apg13, the affinity of which for Apg1 significantly decreases upon hyperphosphorylation, resulting in reduced Apg1 kinase activity (Kamada et al., 2000; Scott et al., 2000) and concomitant activation of the Cvt pathway. Administration of rapamycin or inaccessibility to nutrients, in contrast, leads to inhibition of TOR protein kinase and subsequent dephosphorylation of Apg13. The resulting increase in the activity of Apg1 thus prompts autophagy (Gozuacik and Kimchi, 2004). In this circumstance, autophagy is mediated through macroautophagy and mitophagy (Popp and Segatori, 2015). In the former, the PI3K/Akt and MAPK/ERK1/2 pathways become initiated and are then succeeded by inhibition of mTOR and activation of beclin 1/Atg6. Mitophagy, however, is triggered after mitochondrial damage and the activity of ubiquitin-like conjugation systems. Further down the cascade, an interaction between p62 and LC3-II results in cargo delivery to autophagic membranes or phagophores. Fusion of the phagophores surrounding the cargo material results in formation of autophagosomes, structures that subsequently bud into lysosomes to form autophagolysosomes or degradation center. ROS can induce autophagy through several different mechanisms: nuclear PTEN, the PI3K pathway, and LKB1/AMPK. Rapamycin acts as an mTOR inhibitor (Popp and Segatori, 2015; Diaz-Troya et al., 2008). Rubicon, 3-MA, and chloroquine function to inhibit autophagy (Zhang et al., 2014b; Rebecca and Amaravadi 2016). Activation of p53 leads to upregulation of DRAM and sestrin 1/2, which ultimately accelerates autophagy. p70S6K might be a good option for controlling autophagy downstream to mTOR (Gozuacik and Kimchi, 2004). ALFY, autophagy-linked FYVE protein; Ambra, activating molecule in beclin 1-regulated autophagy; AMPK, AMP-activated protein kinase; BNIP3, BCL2 and adenovirus E1B 19 kDa-interacting protein 3; BNIP3L/NIX, BNIP3-like; ERK, extracellular signal-regulated kinase; FIP200, focal adhesion kinase family interacting protein of 200 kDa; GBL,  $\gamma$ -butyrolactone; HMGB1, high mobility group box protein 1; LIR, LC3-interacting region; LKB1, liver kinase B1; MAPK, mitogen-activated protein kinase; MEK, MAPK kinase; NBR1, neighbor of BRCA1; PE, Phosphatidylethanolamine; P150, a mammalian homolog of yeast Vps15; P53, tumor protein p53; PARL, presenilin-associated rhomboid-like protein; PRAS40, proline-rich Akt substrate of 40 kDa; p70S6K, ribosomal protein S6 kinase  $\beta$ -1; PTEN, phosphatase and tensin homolog; Raf, rapidly accelerated fibrosarcoma; RAPTOR, regulatory-associated protein of mTOR; Ras, rat sarcoma; SQSTM1/p62, sequestosome-1; ub, ubiquitin; ULK1, Unc-51-like kinase 1.

neurologic disease, infection, myopathy, inflammation, aging, and a variety of cancers (Choi, 2012; Yin et al., 2016). To our knowledge, the process of autophagy depends on the continuous presence of ATP along with uninterrupted protein synthesis (Gozuacik and Kimchi, 2004). Figure 1 represents involved signaling pathways.

**Phosphatidylinositol 3-Kinase Complex.** Phosphatidylinositol 3-kinase (PI3K) pathway is primarily involved in the autophagy process (Petiot et al., 2000). The pathway is of crucial importance for endocytic and phagocytic trafficking and formation of autophagic vesicles (Mizushima et al., 2001; Simonsen and Tooze, 2009; Burman and Ktistakis, 2010). According to several studies, 3-methyladenine (3-MA), an autophagy inhibitor, and Wortmannin, a phosphatidylinositol 3-kinase inhibitor, can inhibit the generation of autophagosome precursors in mouse embryonic stem cells (Mizushima et al., 2001).

**Tor Kinase and Apg Expression.** Considered a gatekeeper against the triggering factors of autophagy (Liang, 2010), Tor kinase plays a role in Akt signaling pathway by relaying growth factor-induced signals to the main pathway of autophagy. Accordingly, Tor kinase inhibitors, e.g., rapamycin, can induce autophagy in both yeast and mammalian cells (Díaz-Troya et al., 2008). Inhibition of Tor kinase pathway is thought to increase *Apg8* expression (Kirisako et al., 1999), which is an important gene in formation and expansion of autophagic vesicles (Gozuacik and Kimchi, 2004). Phosphorylation of certain proteins in this pathway coincides with suppression of autophagy in mammalian cells (Blommaert et al., 1997).

**Ubiquitin-Like Systems.** Formation of autophagic vesicles relies on two major ubiquitin-like conjugation systems. In the more predominant systems, an E1-like enzyme called Apg7 is conjugated with Apg12 and then translocated to an E2-like enzyme, Apg10 (Shintani et al., 1999). Next, a covalent linkage is formed between the C terminus of Apg12 and the central part of the Apg5 protein (Mizushima et al., 1998). Nearly all Apg12 molecules in cells are conjugated with Apg5. In this case, Apg12/Apg5 conjugation is not affected by stimuli that may otherwise induce autophagy (Gozuacik and Kimchi, 2004).

## Apoptosis

Type I cell death or apoptosis is a cellular process characterized by the fragmentation of the cell into smaller membraned structures called an apoptotic body, which usually succeed alterations in the nucleic material—namely, condensation of chromatin and degradation of the DNA. The remaining components of the cell are then digested by phagocytes after heterophagocytosis (Gozuacik and Kimchi, 2004).


Apoptosis is usually mediated via two different cascades, the extrinsic and intrinsic pathways, that result in degradation of cellular organelles (Nagata, 2018). The extrinsic apoptotic pathway involves membranous death receptors like CD95 (FAS), TRAIL receptors, and tumor necrosis factor (TNF) receptor family, which bind to specific ligands such as soluble TNF. Upstream to these receptors, there are several caspases that function to mediate the process. Caspase-8 and caspase-10 activate the effector caspases, known as caspase-3, -6, and -7, resulting in final-stage molecular degradation involved in apoptosis (Andreeff, 2003). Mitochondria are the central part of the intrinsic pathway of apoptosis. Proapoptotic molecules such as Bcl2-associated death, Bax, Bak,

Noxa, Bid, and p53 upregulated modulator of apoptosis constitute the intrinsic apoptotic pathways. In this case, Bak and Bax can dimerize and, therefore, permeabilize the outer membrane of mitochondria. As a result, cytochrome C is released into the cytosol and interacts with apoptotic protein activating factor-1, leading to the assembly of apoptosome. This multiprotein structure can activate caspase-9 and other effector caspases (Kang and Reynolds, 2009).

## Autophagy and Apoptosis: Possible Links and Differences

The link between autophagy, apoptosis, and other types of cell death is an area of interest to researchers (Kang et al., 2011), especially in cancer research. Apoptosis is one type of programmed cell death that can be triggered by intra- or extracellular stimuli through activation of a cascade of proteases (Nagata, 2018). On the other hand, autophagy or cellular “self-eating” is a mechanism in which a section of the cell is surrounded by a special intracellular membrane, and its contents are then digested by lysosomal enzymes (Hurley and Young, 2017). Autophagy is like a double-edged sword since it is often induced as a response to stress to prevent cell death through apoptosis ras homolog I (ARHI)-dependent pathway. Nonetheless, in some special occasions, it can serve as a means of cell death (Fulda et al., 2010).

There are contradictive data on the interaction between autophagy and apoptosis. Several stressors can trigger autophagy, e.g., apoptosis-inducing chemotherapeutic agents (Verfaillie et al., 2010), dysfunction of cellular organelles (Anding and Baehrecke, 2017), starvation (Li et al., 2013b), etc. Exposure to such stressors might activate autophagy, which can restore the cell to its normal status. But, in the long-term, the cell may undergo apoptosis. It can be concluded that unlike apoptosis, autophagy is a pathway toward survival of the cell; however, should there be prolonged exposure to stress, the cell may die by means of autophagic cell death (Shen et al., 2012). Figure 2 represents the link between autophagy and apoptosis.



**Fig. 2.** Correlation of apoptosis and autophagy. Oxidative stress, pathogens, and cell death signals can induce autophagy or apoptosis through either dependent or independent pathways. [Modified from Gozuacik and Kimchi (2004).]


**Implications in Cancer.** Not only are autophagy and apoptosis independent, but they also have multiplex crosstalk with each other in physiologic and pathologic incidents like cancer. The tumor-suppressing function of apoptosis is supported by the recent evidence (Chao et al., 2006); however, autophagy is a rather different mechanism that serves as an intricate function in the onset and development of tumors (Sun et al., 2013). Unlike apoptosis, the function of autophagy in tumor cells is partly favorable and partly unfavorable; hence, it can both instigate and halt tumor development (Eskelinen, 2011). It has been argued that cancer cells benefit from autophagy, as it enables them to survive the exposure to several tumor microenvironment stressors such as hypoxia, starvation, and metabolic stresses (Dikic et al., 2010). Besides cancer, other diseases can also occur with this mechanism because of the abnormal balance between autophagy and apoptosis or linkage gene concept. For instance, *Atg5* deficiency can induce apoptosis as a result of stress to endoplasmic reticulum and lead to cardiovascular diseases (Nishida et al., 2008).

### Can Autophagy Hinder or Aggravate Cancer?

Defects in autophagy contribute to the etiology of many diseases, such as cancer (Kondo and Kondo, 2006). Most

studies have indicated the ambivalent nature of autophagy in cancer (Fiaschi and Chiarugi, 2012). Likewise, a remarkable body of published studies have pointed to the function of autophagy in tumor suppression (Mei et al., 2014). Accumulating evidence indicates that there might be a link between cancer and autophagy at two levels of cancer progression and cancer prevention. For example, inactivation of some autophagy genes has been shown to lead to increased tumorigenesis in mice (Ni et al., 2014). On the other hand, enforced expression of certain autophagy genes was reported to prevent formation of tumors (Levine, 2007). It has also been noted that autophagy can be activated in response to chemotherapeutic drugs in cancer cells (Karantza-Wadsworth and White, 2007). Figure 3 and Table 1 represent the correlation between autophagy and tumorigenesis.

A series of in vitro experiments showed that enhanced activity of beclin 1, an autophagy-inducing protein, might reduce the proliferation of cancer cells (Liang et al., 1999). It was also revealed that downregulation of beclin 1 might promote the tumorigenicity of Hela cells (Wang et al., 2007b). In another study, scientists were able to show that beclin 1 overexpression by RNA interference methods reduced the proliferation and migration of cancer cells, introducing this protein as a potential target for cancer treatment modalities (Sun



**Fig. 3.** Autophagy in tumor cells. Oncogene products (blue) inhibit autophagy, whereas tumor suppressors (green) accelerate autophagy, except for cytoplasmic p53. Growth factor signaling through activation of the PI3K/Akt/mTOR axis leads to inhibition of autophagy. On the contrary, class III PI3K activates autophagy. Low levels of cellular energy with an increased AMP/ATP ratio activate the LKB1-AMPK-mTOR pathway, which ultimately results in upregulation of autophagy. p53 is a complex regulatory factor in the process of autophagy, as nuclear p53 activated by genotoxic or oncogenic stress positively regulates autophagy by inhibiting mTOR in an activated AMPK- and TSC1/TSC2-dependent manner. In contrast, cytoplasmic p53 has a negative regulatory effect on autophagy. Autophagy can also be induced by the cell death-associated protein kinase (DAPK) and the death-associated related protein kinase 1 (DRP1). AMPK, AMP-activated protein kinase; Bad, Bcl2-associated death; Bnip3, BCL2 and adenovirus E1B 19 kDa-interacting protein 3; ERK, extracellular signal-regulated kinase; Foxo3A, forkhead box class O 3a; IRS, insulin receptor substrate; LKB1, liver kinase B1; MEK, MAPK kinase; mLST8, mammalian lethal with Sec13 protein 8; P16, CDKN2A; P21, cyclin-dependent kinase inhibitor 1A; P27, cyclin-dependent kinase inhibitor 1B; P53, tumor protein p53; PRAS40, proline-rich Akt substrate of 40 kDa; PTEN, phosphatase and tensin homolog; Puma, p53 upregulated modulator of apoptosis; Raf1, rapidly accelerated fibrosarcoma; Raptor, regulatory-associated protein of mTOR; Ras, rat sarcoma; RB, retinoblastoma; Rheb, Ras homolog enriched in brain; Sestrin, cysteine sulfinic acid reductase; TAK1, TGF- $\beta$ -activated protein kinase 1; TSC, tuberous sclerosis protein. [Modified from Choi (2012).]

TABLE 1  
Correlation between autophagy and tumorigenesis

In Vitro	In Vivo	Autophagy-Related Genes/Signaling Pathways	Autophagy-Related Gene Status in Cancer	Techniques	Autophagy Interaction with TSG	Autophagy Interaction with Oncogenes	Correlation	Ref
Cancer Prevention								
MCF-7 cells	Nude mice	Mammalian: <i>Bec-1</i> Yeast: <i>apg6/vps30</i>	Monoallelic deletion of <i>Bec-1</i> in 40%–75% of sporadic human BC	Gene-transfer techniques to induce <i>Bec-1</i>	—	Bcl-2	<i>Bec-1</i> activation: Inhibition of proliferation of MCF7 cells and clonogenicity, Inhibition of tumorigenesis in nude mice	(Liang et al., 1999)
Hela cells	Athymic nude mouse (SPF) bearing- human cervical cancer	<i>Bec-1</i> (17q21)	<i>Bec-1</i> monoallelically deleted in BC	<i>Bec-1</i> silencing using RNA interference	Cas-9	—	siRNA against <i>Bec-1</i> transfectants: Promoted cell proliferation, Less apoptosis <i>Bec-1</i> -expressing cells: Promoted the autophagy cell death, Regulation of the <i>Cas-9</i> expression, Inhibition of tumorigenesis in nude mice	(Wang et al., 2007b)
CaSki cells	—	<i>Bec-1</i>	<i>Bec-1</i> monoallelically deleted in BC	pcDNA3.1- <i>Bec-1</i> and RNA interference vector pSUPER- <i>Bec-1</i> Bufalin isolated from a TCM, siRNA transfection	—	<i>VEGF</i> and <i>MMP-9</i>	<i>Bec-1</i> overexpression: Decreased <i>VEGF</i> and <i>MMP-9</i> , Cell cycle arrest in the G0/G1 phase, Inhibited invasion and metastasis	(Sun et al., 2011b)
HT-29 cells, Caco-2 cells	—	LC3-II, Atg5, <i>Bec-1</i>	—	Bufalin isolated from a TCM, siRNA transfection	—	—	bufalin activated autophagy through: LC3-II accumulation, Stimulation of autophagic flux, ROS generation, JNK activation, Increased expression of <i>ATG5</i> and <i>Bec-1</i> , autophagy-mediated cell death	(Xie et al., 2011)
SiHa, A549, and MCF-7 cells	—	<i>LC3-I</i> p53/ AMPK/mTOR	—	DHA treatment, GFP-LC3 expression vector	p53, Cas-3	—	DHA treatment: Cas-3-dependent apoptosis and autophagy induction, p53 loss, Increased active form of AMP-activated protein kinase and decreased the activity of mammalian target of rapamycin	(Jing et al., 2011)
SK-HEP-1 cells	—	LC3-I, <i>Bec-1</i> , Atg, AMPK and AKT signaling molecules	—	Kaempferol treatment, GFP-fluorescent LC3 assays	Cas-3	—	Kaempferol treatment: Autophagy induction, Increased protein level of p-AMPK, LC3-II, Atg5, Atg7, Atg12, and <i>Bec-1</i> , Inhibited the levels of CDK1, cyclin B, p-AKT and p-mTOR, G <sub>2</sub> /M arrest, Long-term cancer prevention	(Huang et al., 2013)

TABLE 1 continued

In Vitro	In Vivo	Autophagy-Related Genes/Signaling Pathways	Autophagy-Related Gene Status in Cancer	Techniques	Autophagy Interaction with TSG	Autophagy Interaction with Oncogenes	Correlation	Ref
HeLa, BT-474, SKBR3, and MDA-MB-361 cells	C57/B6 Becl1 knock-in Becn1F121A mice, FVB/N-Tg (MMTVneu) 202 Mul/J strain	<i>Bec-1/BECN1</i> , <i>LC3-I</i>	Allelic loss of <i>Becn1/BECN1</i> in HER-T positive BC	Genetically engineered mutation in <i>Becn1</i> , GFP-LC3 mice, Tat-Bec-1 treatment (autophagy-inducing peptide)	—	HER-2	Mice with a genetically engineered mutation in <i>BECN1</i> : Protected from HER2-driven mammary tumorigenesis, HER2 failed to inhibit autophagy Mice under treatment with Tat-Bec-1: Inhibition of tumor growth as effectively as a clinically used HER2 TKI, Disruption of HER2/Beclin-1 binding, Robust induction of autophagy	(Vega-Rubín-de-Celis et al., 2018)
Cancer Promotion								
MDA-MB-231, HTB43, HTB35, A549, and SW707 cells	—	<i>Bec-1</i> , <i>atg3</i> , <i>atg4b</i> , <i>atg4c</i> , <i>atg5</i> , and <i>atg12</i>	Irradiation-induced accumulation of autophagosomes accompanied by strong mRNA induction of the Atg in tumor cells	Blockade of each Atg through specific target siRNAs, radiation therapy	p53	—	Short-time inhibition of autophagy along with radiotherapy: Strongly diminished accumulation of autophagosomes, Sensitization of resistant carcinoma cells to therapy	(Apel et al., 2008)
IGR-Heu cell line, Heu171 cell clone, B16-F10 cells	C57BL/6 mice with B16-F10-engrafted tumors	<i>Bec-1</i> , <i>Atg5</i> , <i>p62/SQSTM1</i> , <i>pSrc</i> , <i>pSTAT3</i> , <i>HIF-1a</i>	Hypoxia-induced autophagy in tumor	Inhibition of autophagy by siRNA, HCQ treatment, TRP-2 180–188 peptide vaccination	—	—	Hypoxia-induced autophagy in tumor cells: Promoted tumor cell resistance to specific CTL lysis by a mechanism dependent on pSTAT3 Simultaneous inhibition of autophagy in tumor and stimulation of the immune system, HCQ treatment: Inhibited tumor growth in vivo significantly	(Noman et al., 2011)
TOV112D, TOV21G, OV90, SKOV3, MDAH2774, and ES2	C57BL/6 mouse	p62	—	Bortezomib treatment, RNA interference	—	ERK	Bortezomib blocked the autophagic flux through: Inducing ERK phosphorylation, Suppressing cathepsins (B), Inhibiting protein degradation in lysosomes, Enhancing chemotherapy efficacy in ovarian cancer	(Kao et al., 2014)

A549 cell, lung cancer cell; BC, breast cancer; Bec-1, beclin 1; B16-F10 cell, melanoma tumor cell; Caco-2, human colon cancer cell; Cas-3, caspase 3; Cas-9, caspase 9; CaSki cell, cervical cancer cell; CTL, cytolytic T lymphocyte; DHA, docosahexaenoic acid; ES2, human ovarian cancer cell; HCQ, hydroxychloroquine; HeLa cell, cervical cancer cell; HIF-1a, hypoxia-inducible factor; HT-29, human colon cancer cell; HTB35 cell, cervical squamous cell carcinoma cell; HTB43 cell, pharyngeal cancer cell; IGR-Heu, lung carcinoma cell line; JNK, c-Jun NH2-terminal kinase; MCF7, human breast carcinoma cell line; MDAH2774, human ovarian cancer cell; MDA-MB-231 cell, breast cancer cell; MDA-MB-361 cell, breast cancer cell; OV90, human ovarian cancer cell; pSrc, Src kinase; SiHa cell, cancer cells harboring wild-type p53; SiHa cell, human cervical cancer; siRNA, small interfering RNA; SK-HEP-1 cell, human hepatic cancer cell; SKOV3, human ovarian cancer cell; SPF, Athymic nude mouse; SW707 cell, rectum carcinoma cell; TCM, bufalin isolated from a traditional Chinese medicine; TKI, tyrosine kinase inhibitor; TOV112D, human ovarian cancer cell; TOV21G, human ovarian cancer cell; TRP-2 180–188 peptide, tyrosinase-related protein-2 peptide; TSG, tumor suppressor gene; VEGF, vascular endothelial growth factor.

et al., 2011b). In 2011, scientists reported that induced autophagy by means of docosahexaenoic acid could augment the apoptosis rate by affecting caspase-3 function in cancer cells (Jing et al., 2011). It was only 2 years later that another investigation confirmed the desirable effects of kaempferol in treatment of cancer cells, which included arrestment of cell cycle and induction of autophagic cell death (Huang et al., 2013). Several years later, it was reported that a treatment regimen comprising beclin 1-derived protein hindered the proliferation of HER2-positive breast cancer cells (Vega-Rubín-de-Celis et al., 2018). It was also shown that most important autophagy-related genes, like *beclin1*, *atg5*, *bif-1*, and *atg4c*, had been lost in the genome of prostate, ovarian, and breast cancer cells (Maes et al., 2013). Allegedly, a combined therapy of autophagy targeting and radiotherapy might prove to be more effective than radiotherapy alone. Accordingly, downregulation of *beclin-1*, *atg3*, *atg4b*, *atg4c*, *atg5*, and *atg12* could sensitize cancer cells to radiation (Apel et al., 2008). Recently, cisplatin-induced autophagy in ovarian cancer was inhibited by bortezomib, a proteasome inhibitor, to increase the efficacy of chemotherapy (Kao et al., 2014). Bufalin, in a similar way, causes autophagy-mediated cell death through ROS production and enhanced radiosensitivity in human colon cancer cells (Xie et al., 2011).

Thus, it can clearly be inferred that autophagy should not be considered a definitive solution, but rather, it should be regarded as a doubtful advantage with two sides, each of which have been well supported by several investigations. (Jiang et al., 2019). Through the removal of damaged DNA and organelles in the preliminary stages of tumorigenesis, autophagy acts as a protective mechanism to maintain the integrity of the cell and prevent instigation of malignancy (Hönscheid et al., 2014). A pivotal mechanism for migration and invasion of tumor cells, epithelial-to-mesenchymal transition (EMT) can be counteracted by induction of autophagy, thus hindering tumorigenesis (Lv et al., 2012; Catalano et al., 2015). However, as the tumors progress in stage, autophagy assumes a seemingly paradoxical role by delivering essential nutrients to the tumor cells through degradation of unnecessary intracellular structures, resulting in the emergence of resistant tumor cells (Cheong, 2015). Therefore, development of an effective autophagy-based cancer therapy for the treatment of malignancies is a rather complicated task for clinicians (Jiang et al., 2019).

For centrally located tumor cells, autophagy can be an excellent option for cancer cells to survive and continue tumorigenesis. In this case, autophagy may function as a big barrier against most routine cancer therapies (Kimmelman, 2011). Unlike the aforementioned data, dozens of studies have revealed that autophagy is another side of the sword that can help with the maintenance of tumor cells (Gong et al., 2013; Guo et al., 2016), as it contributes to their escape from the immune system (Noman et al., 2011). Table 2 summarizes the autophagic genes involved in cell death, invasion, and tumor dormancy (Liang et al., 2006; Wang et al., 2007a; Criollo et al., 2009; Kang et al., 2009; Mathew et al., 2009; Dimco et al., 2010; King et al., 2011; Capparelli et al., 2012; Gundara et al., 2012; Schmitt et al., 2012; Wu et al., 2012, 2013; Kenzelmann Broz et al., 2013; Lindqvist and Vaux, 2014; Maes et al., 2014; Murthy et al., 2014; Fernández and López-Otín, 2015; Poillet-Perez et al., 2015; Richmond et al., 2015; Su et al., 2015; Washington et al., 2015; Xie et al., 2015; Attar-Schneider et al., 2016; Cubillos-Ruiz et al., 2017; El

Andaloussi et al., 2017; Galluzzi et al., 2017; Karch et al., 2017; Aqbi et al., 2018a; Chen et al., 2018a; Cusan et al., 2018; Liu et al., 2018b,c; Maruyama and Noda, 2017; Tong et al., 2018; Vera-Ramirez et al., 2018; La Belle Flynn et al., 2019; Li et al., 2020).

## Nanotechnology

A large number of studies have been conducted on wide-ranging applications of nanomaterials (NMs) only to discover their peculiarly unfavorable effects. In terms of cell function and molecular pathway, NMs often cause profound adverse biologic effects (Setyawati et al., 2013a; Tay et al., 2013; Afzalipour et al., 2019; Shirvalilou et al., 2020). Nanotechnology has multiple applications with a scientific impact; however, the underlying pathways in interaction of NMs with biologic systems at a molecular level still remain to be elucidated. These controversies raise concerns for utilizing nanoscale particles in targeted cancer therapies (Warheit, 2010; Setyawati et al., 2013b; Changizi et al., 2020b).

## The Link between Autophagy and Nanotechnology

NPs have been widely used as beneficial research tools for modulating the process of autophagy. Autophagy abnormalities are associated with several disorders, including cancer and cardiovascular, metabolic, and neurodegenerative diseases (Ghavami et al., 2014). Hence, NP-related autophagy modulations are suggested to be a state-of-the-art therapeutic intervention for treatment of such conditions. Induction of oxidative stress-dependent signaling (ER stress, mitochondrial damage, etc.), inhibition of Akt-mTOR signaling, and alteration of the expression of autophagy-related gene/protein stand among the primary mechanisms by which NMs modulate autophagic pathway (Wu et al., 2014). Figure 4 and Table 3 represent the link between autophagy and nanotechnology in cancer.

### Can NMs Turn On or Turn Off Autophagy? Which One Is Preferable for Killing Tumor Cells?

The paradoxical nature of autophagy can be turned into an advantage for development of cancer treatment modalities, as the mechanism is thought to be a driving factor of early survival and late cell death in tumor progression and cancer therapy (Singh et al., 2018). Thus, the role of NMs in cancer therapy enhancement is incontrovertible (Beik et al., 2017; Ghaznavi et al., 2018; Abed et al., 2019; Beik et al., 2019; Mirrahimi et al., 2019). In the last decade, inhibition of autophagy was introduced as a strategic mechanism in cancer therapy. A growing number of studies are being dedicated to delineating the link between NMs and autophagy to see whether NMs are exploitable tools in cancer therapies (Wei and Le, 2019). Since then, an expanding number of NMs ranging from soft NMs, liposomes, and polymeric NPs to hard NMs such as cerium dioxide NPs, zinc oxide, iron oxide (IONPs), silver, gold, and titanium dioxide NPs, QDs, carbon nanotubes (CNTs), graphene oxide, silica NPs, and fullerenes have been shown to possess remarkable properties for modulating autophagy (Hussain et al., 2012; Yu et al., 2014b; Zheng et al., 2016). Chemical composition, morphology, and

TABLE 2

The autophagic genes involved in cell death, invasion, and tumor dormancy

Gene Name	Cellular Pathway	Effector	Consequences	Ref.
<b>Autophagic Genes Involved in Cell Death (Autophagic, Apoptotic)</b>				
Dormancy activation	P53 overexpression induced by Cdkn1b	Pentose phosphate pathway destruction, Increased ROS	Cell death, Dormancy induction by IFN- $\beta$	(Liu et al., 2018b)
FasL (CD95L or CD178), TRAIL, and TNF- $\alpha$ activation	DISC formation	Cas-3, 6 and 7 activation, Bid change into tBid	Directly cell death, Mitochondria-dependent apoptotic cell death	(Su et al., 2015)
Autophagy inhibition	ATG7 depletion	Accumulation of damaged mitochondria, Increase of ROS, Increase of apoptosis	Killing of dormant cells, Has no any effect on cell metastasis and proliferation	(Vera-Ramirez et al., 2018)
Autophagy activation	TMEM166 overexpression	High LC3II/LC3I Vacuolization Mitochondria membrane permeabilization	Autophagy and apoptosis regulator (autophagic and apoptotic cell death)	(Wang et al., 2007a)
IRGM	—	Negative regulation of IFN signaling	Autophagic cell death	(King et al., 2011)
Increase of Bax and Bak1	Inactivation of Bak1 and Bax	Intrinsic pathway (mito), indirect effect on the autophagy ARHI-dependent	Increase cancer cell apoptosis	(Karch et al., 2017; Lindqvist and Vaux 2014)
DAPK1	—	ARHI-dependent	Tumor suppressor, Apoptotic cell death	(Wu et al., 2013; Tong et al., 2018)
PTEN	Autophagy activation	PI3K/Akt inhibition, PI3K/AKT/mTORC1 inhibition	Tumor suppressor	(Gundara et al., 2012)
PTEN	PTEN inhibitors	Tsc1 or Tsc2, p27 and Foxo3a	Escape from dormancy	(Richmond et al., 2015; Chen et al., 2018a)
PTEN	Apoptosis modulator activation	DRAM, DAPk and DRP-1, PTEN, E93, Akt/PKB and mTOR, Bcl-2 family proteins, TRAIL and bec-1	Autophagy acts as upstream control of apoptosis death	(Wang et al., 2007a)
Autophagy abortion	DRAM1 overexpression	By p53	Apoptotic death	(Criollo et al., 2009)
<b>Autophagic Genes Involved in Invasion (Colonization, Proliferation, Tumor Formation, Promotion, Metastasis)</b>				
ATG5 and ATG7- RAS	Increased autophagy	Mitochondria activation	Tumor formation	(Li et al., 2020; Gundara et al., 2012)
Autophagy inhibition	Cas-3/ATG16L1 complex formation	Sustained intracellular stress and pathogen	Disease or tumor promotion	(Murthy et al., 2014)
Autophagy deficiency	ATG4D deficiency	Intracellular LC3-B/ P62 accumulation, Autophagosome formation abortion	Disease and tumor promotion	(El Andaloussi et al., 2017)
Autophagy activation	ATG5/7 increased	—	Increase in colonization	(Washington et al., 2015)
Autophagy activation	p27Kip1 coded by CDKN1B	CDK-dependent kinase inhibitor	Tumor promotion	(Cusan et al., 2018)
Autophagy deactivation	ATG3/7/p62 targeting	Pfkfb3 normal expression	Tumor repopulation	(La Belle Flynn et al., 2019; Mathew et al., 2009)
STAT1 inhibition	p27 (CDKN1B), p21(CDKN1A) upregulation	Increase in IDO1 and Kyn receptors, Rb hypophosphorylation, suppress E2F transcription factor activity	Tumor dormancy, Increase in colony formation, Decrease in proliferation	(Wu et al., 2012)
ATG9B	Autophagy deregulation	—	Tumorigenesis	(Li et al., 2020; Kang et al., 2009)
Autophagy manipulation	eIF4E/eIF4GI knockdown	Decrease in ER $\alpha$ , SMAD5, NF-kB, CyclinD1, c-MYC, and HIF1 $\alpha$	Decrease in EMT promoter, Increase in EMT inhibitors, Decrease in migration capability	(Attar-Schneider et al., 2016)

TABLE 2 continued

Gene Name	Cellular Pathway	Effector	Consequences	Ref.
Autophagic Genes Involved in Dormancy (Suppression, Inhibition, Resistance to Anoikis, Invasiveness and Colonization, Recurrence)				
Activation of Nix/ BNIP3L+ GABARAPL1+ GABARAP	Autophagy activation and deletion of damaged Mitochondria	Increase ROS	Tumor suppression	(Poillet-Perez et al., 2015)
ATG5 and ATG7 deletion	Autophagy inhibition	Oxidative stress, Damaged Mitochondria	Tumor suppression	(La Belle Flynn et al., 2019)
ATG16L1, Bec-1, and LC3-II degradation	Autophagy deficiency	Oxidative stress Damaged Mitochondria, Inflammation (IL-1 $\beta$ , IL-18)	Tumor suppression	(Fernández and López- Otín 2015; Maruyama and Noda, 2017)
High Atg4B	Autophagy inhibition	LC3-PE degradation, LC3 sequestration in cytosol	Tumor suppressive	(Galluzzi et al., 2017)
Autophagy activation	DNA damage	Atg4a and Atg4c/p53 contribution	Tumor suppression by p53-mediated apoptosis	(Kenzelmann Broz et al., 2013)
Autophagy deficiency	ATG16L1 overexpression (nonspecific organs)	—	Tumor formation suppression	(Capparelli et al., 2012)
Autophagy deficiency	UVRAG upregulation	—	Tumor suppression	(Liang et al., 2006)
Autophagy deficiency	ATG5 and ATG12 deficiency	Decreased survival capacity to metabolic stress	Tumor suppression (decrease in colonization and survival capability)	(Maes et al., 2014)
Dormancy activation	P53 overexpression induced by Cdkn1b	Pentose phosphate pathway destruction, Increased ROS	Cell death, Dormancy induction by IFN- $\beta$	(Liu et al., 2018c)
ER stress	K-RAS dependent Eif2ak3-/- MEFs	Decrease in VCIP and PDGFRB (angiogenic stabilizer)	Tumor suppression, ECM destruction, Vast hemorrhage	(Cubillos-Ruiz et al., 2017)
BBC3/ HSPA8(HSC70) complex formation	CMA	Cargo delivery to lysosome	Tumor protection by autophagy	(Xie et al., 2015)
IFN- $\gamma$ /STAT1 activation	Downregulation of cyclin E, A, D1, 2, 3	Downregulation of CDK4 and CDK6	Cell cycle arrest, Cancer cell dormancy	(Dimco et al., 2010; Schmitt et al., 2012)
Inherent ATG5 or autophagy KO	Intracellular inherent autophagy	Postpone recurrence	Recurrence, chemotherapy desensitization, increase of dormancy frequency	(Aqbi et al., 2018a)
ER stress	EIF2AK3 suppression	Upregulation of FGF2, VEGF, and IL-6 Downregulation of THBS1, CXCL14, and CXCL10	Suppression of angiogenesis and tumor promotion Tumor suppression	(Cubillos-Ruiz et al., 2017)

BBC3, Bcl-2-binding component 3; bec-1, beclin-1; Cas, caspase; CD178, Fas ligand or CD95L; CDK4, cyclin-dependent kinase 4; CDK6, cyclin-dependent kinase 6; CDKN1B, cyclin-dependent kinase 1B; CD95L, CD95 ligand; CMA, chaperon mediated autophagy; c-MYC, avian myelocytomatosis virus oncogene cellular homolog; CXCL10, C-X-C motif chemokine 10; CXCL14, C-X-C motif chemokine 14; CDKN1B, cyclin-dependent kinase 1B; CDKN1A, cyclin-dependent kinase1A; DAPK, death-associated protein kinase; DRP-1, dynamin-related protein 1; E93, transcription factor E93; ECM, extracellular matrix; E2F, transcription factors; eIF, eukaryotic translation initiation factor; ER $\alpha$ , estrogen receptor alpha; FasL, FasL or CD95L or CD178; FGF2, fibroblast growth factor 2; Foxo3a, forkhead box O3; GABARAP, GABA receptor-associated protein; GABARAPL1, GABA receptor-associated protein-like 1 precursor - *Homo sapiens*; HIF1 $\alpha$ , hypoxia-inducible factor 1 $\alpha$ ; HSPA8(HSC70), heat shock 70 kDa protein 8; IDO1, indoleamine 2,3-dioxygenase 1; IL, interleukin; IRGM, immunity-related GTPase M; KO, knocked out; K-RAS, Ki-ras2 kirsten rat sarcoma; Kyn, kynurenine; LC3-B/P62, microtubule-associated protein light chain 3-B/sequestosome 1; LC3-PE, microtubule-associated protein light chain 3-phosphatidylethanolamine; MEF, mouse embryonic fibroblast; Mito, mitochondria; mTOR, mammalian target of rapamycin; NF-kB, nuclear factor kappa-light-chain-enhancer of activated B cells; Nix/BNIP3L, NIP-like protein X/BCL2 interacting protein 3 like; p21, cyclin-dependent kinase inhibitor 1; p27, cyclin-dependent kinase inhibitor 1B; P53, tumor suppressor protein p53; PDGFRB, platelet-derived growth factor receptor beta; Pfkfb3, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3; p27Kip1, p27Kip1; PTEN, phosphatase and tensin homolog; Rb, retinoblastoma protein; SMAD5, receptor-regulated SMAD; STAT1, signal transducer and activator of transcription 1; tBid Cdkn1b, truncated Bid cyclin-dependent kinase inhibitor 1B; THBS1, thrombospondin 1; TMEM166, transmembrane protein 166; TNF- $\alpha$ , tumor necrosis factor- $\alpha$ ; Tsc1, tuberous sclerosis 1; Tsc2, tuberous sclerosis 2; UVRAG, UV radiation resistance associated; VCIP, vasoactive intestinal peptide; VEGF, vascular endothelial growth factor.


surface chemistry, as well as the size of NMs, determine whether a NP is likely to trigger autophagy under certain conditions. In other words, NPs can be considered as both inducer and inhibitor of autophagy in the target cell based on their size and morphology (Popp and Segatori, 2015; Zhang et al., 2018).

Nevertheless, NP-mediated autophagy is associated with nanotoxicity (Sarkar et al., 2014). To boost the therapeutic efficacy and develop safer NMs, scientists investigated the variations of CNTs' surface ligand and their impact in modulating the extent to which autophagy is triggered. They

reported that the surface modification of CNTs might result in potential pharmaceutical autophagy modulators and bio-compatible NMs (Wu et al., 2014).

#### Turn-On Effects of NMs. *Positive turn-on effects: prodeath nature of autophagy.*

Various NMs, including metallic-based NPs (Cordani and Somoza, 2019) and light and heavy nanocrystals (Yu et al., 2009), can trigger autophagy. In 2005, scientists showed that nanosized neodymium oxide induced extensive autophagy in NCI-H460 human lung cancer cells (Chen et al., 2005). After that, NM-related autophagy was generally believed to be a



prodeath mechanism. The only way to acquire knowledge on the likelihood of such claims was to evaluate cell death while inhibiting autophagy. For clarification, it was shown that both molecule inhibitors and *Atg5* gene knockdown dramatically reduced the rate of death in HeLa cells incubated with ZnO NPs, indicating that these NMs triggered prodeath autophagy (Hu et al., 2019). This was suggested to be a positive effect of NMs in cancer therapy through the regulation of oxidative stress and autophagy, which led to cell death. In this case, NMs served as cytotoxics and/or enhanced the efficiency of typical chemotherapies (Sun et al., 2014).

To enhance the efficiency of epidermal growth factor receptor (EGFR)-oriented triple-negative breast cancer therapy, scientists developed EGFR-targeted gold NPs to induce autophagy. In this case, autophagy induction rendered the cancer cells more susceptible to photothermal therapy (PTT) (Zhang et al., 2017b). They discovered that poly(lactic-coglycolic acid) (PLGA)-based NPs were able to trigger autophagy in tumor cells. In this modality, NPs were swallowed by autophagosomes before being delivered to degradative organelles

(Zhang et al., 2014b). Modified PLGA-based NPs significantly enhanced the activity of autophagosomes compared with non-modified counterparts. In this study, induction of autophagy via docetaxel-containing NPs contributed to impaired intratumoral drug delivery (Liu et al., 2011).

In another study, redox-responsive nanohybrid GCMSNs were synthesized through gold nanoparticle attachment onto amine-functionalized MSNs. Compared with normal 3T3-L1 cells, GCMSNs induced higher oxidative stress-triggered autophagy in A549 lung cancer cells. Synergism, through the combination of chemotherapy and oxidative stress-induced autophagy via camptothecin-loaded nanohybrids, resulted in a superior nanocarrier system for highly effective cancer therapy (Lu et al., 2015). Despite that, autophagy-mediated cell death is still somehow challenging if the normal cells become involved as well. To address this issue, one should ascertain the selectivity of NP-based autophagy, as it must only be triggered in cancer cells.

The best targets for autophagy-mediated therapy are autophagy-deficient cancer cells. Lack of beclin 1 protein

TABLE 3  
Interaction between nanotechnology and autophagy in cancer

In Vitro	In/Ex Vivo	NPs	Size	Concentration	NP Treatment Effect	Mechanism	Approach	Ref
I. Turn-On Effects of NMs								
Prodeath Nature of Autophagy								
NCL-H460 cells	—	Nano Nd203	Mean diameter: 80 nm	Micromolar equivalent concentration range (40–45 $\mu$ M)	Cytotoxic effects, Apoptosis induction, Autophagic cell death	Massive vacuolization induction, S-phase cell cycle arrest, Mild disruption of mitochondrial membrane integrity, Inhibition of proteasome activity	Therapy	(Chen et al., 2005)
—	—	nC60(Nd)	—	—	Induced autophagy and sensitized chemotherapeutic killing of tumor cells in both normal and drug-resistant cancers	Enhancing the cytotoxicity of chemotherapeutic agents and reducing drug resistance	Therapy	(Wei et al., 2010)
A549 cells, NCI-H1975 cells	BALB/c mice	f-SWCNTs	—	5% COOH-CNT	In vitro: COOH-CNT; Autophagy-induced cell death, In the presence of autophagy inhibitor (3MA), ATG6, or TSC2 siRNA; Increase in cell viability in vivo: Acute lung injury	In vitro (COOH-CNT): Formation of autophagosomes, LC3-II upregulation, Significant decrease in the phosphorylation of mTOR, mTOR's substrate S6 and Akt	Autophagy-blocking reagents as potential agents to remedy the ALI induced by NMs	(Liu et al., 2011)
A549 cells, IMR-90	—	IONPs	Size range: 30–65 nm, average size: 51.34 $\pm$ 14.71 nm	10–100 $\mu$ g/ml	Selective autophagy-induced cell death	Autophagy correlated with ROS production and mitochondrial damage, AMPK/mTOR/PI3K/Akt pathway regulation by a significant reduction in phosphorylated mTOR, Akt, and p70S6K levels, Significant increase in phosphorylated APMK	Therapy	(Khan et al., 2012)
MCF-7 cells	Xenograft SCID mice model	PLGA NPs	100–150 nm in diameter	In vitro: DOX: 0.25–25 mg/ml, 3-MA: 10 mM, CQ: 30 mM, Drug-free PLGA NPs: at the same NP concentration, IC50: PLGA NPs: 38.27 $\pm$ 1.23, 3-MA: 6.7 $\pm$ 1.05, CQ: 4.78 $\pm$ 1.75 mg/ml	Significant enhancement of therapy efficacy through combined cholic acid conjugated DOX- PLGA NPs with autophagy inhibitors (3-MA and CQ)	Cancer cells captured PLGA NPs and degraded by autolysosomes	Clinical application	(Zhang et al., 2014b)

TABLE 3 continued

In Vitro	In/Ex Vivo	NPs	Size	Concentration	NP Treatment Effect	Mechanism	Approach	Ref
I. Turn-On Effects of NMs								
A549 cells, 3T3-L1	A549 lung cancer xenografted nude	GCMSNs: GNPs + MSNs, CPT-loaded GCMSNs)	GNPs: 5 nm in diameter NMSNs: 200 nm	In vivo: 10 mg DTX/kg, 20. 50 mg/kg CQ In vitro: 100 mg/ml In vivo: CPT-loaded GCMSN; CPT concentrations: 2.8, 5.6, 11.2 mM GCMSN: 1, 2, and 4 mg/ml	Growth inhibitory effect, Oxidative stress-triggered mitochondrial-mediated autophagy	Up-taken GCMSNs: blocking pores and inducing production of ROS, mitochondrial dysfunction, oxidative stress-triggered mitochondrial-mediated autophagy, GNPs: as an oxidative stress elicitor  In vitro: Formation of a large number of autophagic vesicles, Significant increase in autophagy-specific proteins LC3, p62, Beclin-1, Atg5, Inhibition of AKT-mTOR signaling pathway  In vivo: Increased LC3 and Beclin-1 levels  In vitro: Promoting Atg5-regulated autophagy flux, Accelerating zinc ion release, Accelerating the intracellular dissolution of ZONs, ROS generation  In vivo: The antitumor therapeutic effect of cotreatment with ZONs or free DOX treatment	Selective and effective cancer Combined chemotherapy	(Lu et al.,2015)
MDA-MB-231 (cultured TNBC cells)	Female BALB/c nude mice with xenograft tumors	GNs, Anti-EGFR-GNs	10 × 40 nm	120 pM	Anti-EGFR-GNs-combined NIR-PTT: Autophagy-induced cell death	  In vitro: Formation of a large number of autophagic vesicles, Significant increase in autophagy-specific proteins LC3, p62, Beclin-1, Atg5, Inhibition of AKT-mTOR signaling pathway  In vivo: Increased LC3 and Beclin-1 levels  In vitro: Promoting Atg5-regulated autophagy flux, Accelerating zinc ion release, Accelerating the intracellular dissolution of ZONs, ROS generation  In vivo: The antitumor therapeutic effect of cotreatment with ZONs or free DOX treatment	Combined targeted therapy	(Zhang et al., 2017b)
Dox-resistant MCF-7 cell line, MCF-7/ADR, HeLa cells, 4T1 cells	4T1 tumor-bearing female BALB/c mice	ZON	Average size: 172 nm = Zetapotential: -5.01 m	In vitro: 50 µg ml <sup>-1</sup> , 100 µg ml <sup>-1</sup> , In vivo: 2 mg kg <sup>-1</sup>	Killed tumor cells, Enhanced tumor chemotherapy both normal and drug-resistant cancer cells, Overcame drug resistance	  In vitro: Promoting Atg5-regulated autophagy flux, Accelerating zinc ion release, Accelerating the intracellular dissolution of ZONs, ROS generation  In vivo: The antitumor therapeutic effect of cotreatment with ZONs or free DOX treatment	Adjunct chemotherapy	(Hu et al.,2019)
Prosurvival Nature of Autophagy								
HeLa cells	—	P-VO <sub>2</sub>	—	—	Induced cytoprotective, rather than death-promoting, autophagy in cultured tumor cells	Upregulation of HO-1 and protecting cells against death under stressful situations	Therapeutic applications	(Zhou et al.,2013)
4T1, MCF7/MDR cells	BALB/c mice, NOD/SCID mice Human	Cu-Pd alloy TNP-1	TNPs: ~50 nm in length	In vitro: 0.5 mg ml <sup>-1</sup> In vivo:	Induced prosurvival autophagy in tumor	Normal autophagy flux without impairment of lysosomal function	Autophagy-inspired chemo-PTT of drug-resistant tumor cells	(Zhang et al., 2018)

TABLE 3 continued

In Vitro	In/Ex Vivo	NPs	Size	Concentration	NP Treatment Effect	Mechanism	Approach	Ref
<b>I. Turn-On Effects of NMs</b>								
	breast infiltrating ductal carcinoma specimens		SNP: 35 nm	1.5 mg CuPd TNPs per kg	cells, Increased cell viability			
<b>II. Turn-Off Effects of NMs</b>								
HeLa cell, HEK293 cells	Tumor-bearing mice	NDs	Primary particle size: 10 nm Hydrodynamic size, in water: 191 nm in cell culture: 289 nm	20–50 µg/ml	Suppressed autophagic flux in cultured cells tumors	Selective induction of PCD in hypoxic cancer cells, Minimal impairment of lysosomal functions, Significant accumulation of in LC3-II and P62, Significant increase in protein levels of Cas-3	Targeted antiangiogenic therapy	(Chen et al., 2018b)
Breast CSCs, ALDH hi, MDA-MB-231, MCF-7 cells	Orthotopic tumor murine model, ICR mice and female NOD/SCID mice	NPCQ, NPDOX, NPDTXL, NPDOX/CQ, NPDTXL/CQ	Similar diameter of about 110 nm	In vitro: 1–15 µg/mL, In vivo: 6.5, 1, and 2 mg/kg	Inhibited nanoparticle-mediated autophagy, Reduced “stemness” and increased susceptibility to chemotherapy drugs	Impairment of endosomal acidification, blocking endosome and autophagosome fusion with lysosomes, Increasing accumulation of LC3-II and p62	Effective therapy	(Sun et al., 2016)
U-87 MG cells	—	NBP/TiO2 nanostructures, CTAB-Capped Au NBPs, Au NBP/TiO2 Nanostructures	Lengths: 47 ± 4, 95 ± 5, 142 ± 8 nm Widths: 20 ± 2, 33 ± 2, 42 ± 3 nm	30 or 60 µg Au ml <sup>-1</sup>	Inhibited autophagic flux leading to cancer cell death	Significant autophagosome accumulation in cancer cells via blocking the autophagosome-lysosome fusion process, inhibiting lysosomal degradation, Reducing the mature cathepsin B, Inhibiting the proteolytic activity of cathepsin B, Inhibiting trypsin-like proteolytic activity, UPS inhibition, Synergistic loss of brain cancer cell viability by combination of	Anticancer agent	(Wan et al., 2017)

A549 cell, human lung adenocarcinoma; ALI, acute lung injury; AMPK, AMP-activated protein kinase; Anti-EGFR-GN, epidermal growth factor receptor-targeted gold nanorod; Bec-1, beclin-1; Cas-3, caspase-3; CPT, camptothecin; CSC, cancer stem cell; Cu-Pd alloy TNP-1, copper-palladium alloy tetrapod nanoparticle; DOX, doxorubicin; f-SWCNT, functionalized single-walled carbon nanotube; GNP, gold nanoparticle; HEK293, human embryonic kidney 293; HO-1, heme oxygenase-1; IMR-90, normal human lung fibroblast cell; Nano Nd2O3, nanosized neodymium oxide; NBP/TiO2, titania-coated gold nano-bipyramid nanostructure; nC60, water-dispersed nanoparticle solution of derivatized fullerene C60; NCI-H460 cell, non-small cell lung cancer cell; NIR-PTT, near-infrared-photothermal therapy; NMSN, amino-functionalized MSN; NSCLC, non-small-cell lung cancer; PCD, programmed cell death; PPT, photothermal therapy; P-VO2, nanosized paramontroseite VO2 nanocrystals; SNP, spherical nanoparticle; 4T1, triple-negative, drug-resistant MCF7/MDR; 3T3-L1, normal cell; TNBC, triple-negative breast cancer; TNP, tetrapod nanoparticle; UPS, ubiquitin-proteasome system; ZON, zinc oxide nanoparticle.

required for initiation of autophagosome formation in autophagy is a determining factor. Therefore, designing autophagy-inducing peptides engineered into polymeric NPs (Bec1) could significantly enhance autophagy-mediated cell death in these cells (Wang et al., 2015a).

NP-induced autophagy sometimes appears to be useful for cancer therapy, especially against drug-resistant variants, if it were coupled with autophagy-mediated chemosensitization. Fullerene c60, which induces autophagy in tumor cells, was reported to enhance the chemosensitization of both normal and drug-resistant cancer cells. Thus, the subsequent reduction in drug resistance may eventually establish novel therapeutic strategies for cancer treatment (Wei et al., 2010).

*Negative turn-on effect: prosurvival nature of autophagy.* To form a verdict on nanorelated autophagy-inducing effect in cancer therapy from another perspective, it is appropriate to note the ineffectiveness of Chemo-PTT combination therapy approach in drug-resistant cancer. Turning on the pro-survival autophagy is thought to be a great solution to this issue. With a high absorption in the near-infrared region, NMs can also induce prosurvival autophagy. The recent application of custom-designed copper (Cu)-palladium (Pd) alloy tetrapod NPs in Chemo-PTT is considered a novel approach that combines chemotherapy and PPT. Thanks to their unique structure, these NPs elicited an ideal photothermal conversion potential and induced prosurvival autophagic cell death. This achievement paved the way for application of custom-designed NPs as autophagy-suppressing agents rather than the conventional therapeutic agents (Zhang et al., 2018). In contrast to the most noted autophagy-related cell death by NMs, nanosized paramontroseite VO<sub>2</sub> nanocrystals were reported to induce cytoprotective autophagy in cultured HeLa cells (Zhou et al., 2013). Furthermore, several NMs were also reported to induce prosurvival autophagy (Zhang et al., 2019).

This increased level of protective autophagy (prosurvival autophagy) could hamper anticancer therapies. In such cases, autophagy might function as a cellular protector against NP-induced cytotoxicity in various tumor cell lines. Therefore, autophagy inhibitors have been widely used in company with drug-delivery NMs to improve the treatment efficiency. Hence, when deciding to modulate autophagy for enhancing treatment efficiency, one should consider whether the combined regimen enhances or dampens autophagic activity in tumor cells to accurately determine the modulation method (Høyer-Hansen and Jäättelä, 2008; Das et al., 2019).

**Turn-Off Effects of NMs.** In addition to the above mechanisms, a number of studies suggest that NMs are capable of perturbing autophagic pathways by inhibiting Akt-mTOR signaling or altering the expression of autophagy-associated genes/proteins (Li et al., 2009; Zhang et al., 2009; Liu et al., 2011). Therefore, compared with the well studied NMs that induce autophagy, inhibitory types are still rare. Citric acid-capped gold, REO, and IONPs have been known as blockers of autophagic activity; however, their mechanism of action and cellular targets are still ill-defined. In a recent study, custom-designed titania-coated gold nano-bipyramids functioned as an innovative autophagy inhibitor for sensitizing U-87 MG brain tumor cells to proteasome inhibitor-induced cell death. Moreover, nanodiamonds (NDs) were recently shown to inhibit autophagy in oxygen-deprived tumors in a

synergistic manner (Wan et al., 2017). In practical terms, high levels of autophagy under hypoxia is an adaptive strategy adopted by cancer cell for survival. Therefore, ND-related autophagy inhibition, along with oxygen deprivation, may cause significant apoptosis in HeLa cells and MCF-7 cells (Chen et al., 2018b). In a similar study led by Sun et al. (2016), inhibition of autophagy resulted in sensitization of MDA-MB-231 cells to conventional chemotherapeutics.

NMs have the potential to either induce or inhibit the autophagic pathways. Still, more research on this topic needs to be conducted to delineate the link between NMs and autophagy.

### Effects of NMs on Tumor Dormancy: Focusing on Involved Signaling Pathways

NPs can influence the autophagic pathway in different ways; however, their role in the induction of tumor dormancy may hinder their practical applications. Autophagy plays a crucial role in preserving tumor cells in a prolonged state of arrest and senescence that can be followed by apoptotic cell death (Polewska et al., 2013). That is to say, autophagy may be directly associated with tumor dormancy, as the senescent cells might recover their proliferative capability, giving rise to renewed tumor growth and metastasis (Gewirtz 2009). Nonetheless, PTT therapy has limited capacity for total eradication of tumor cells, as adjacent cells could be very well damaged by mild hyperthermia. In this case, heat shock proteins would naturally be recruited to repair the damaged cells, resulting in tumor relapse and, eventually, escape of tumor from dormancy (You et al., 2019).

Dormant tumor cells often gain drug resistance that protects them against chemotherapy (Aguirre-Ghiso, 2007). In 2006, scientists established a link between the activation of the p38 signaling pathway and induction of tumor dormancy. They demonstrated how enhanced activation of PERK, an RNA-dependent protein kinase, compels dormant squamous carcinoma cells to develop drug resistance (Ranganathan et al., 2006). Several newly designed NMs were reported to activate p38 signaling and, therefore, induce drug resistance (Eom and Choi, 2010; Skuland et al., 2014). These NMs are conjugated to drugs and circumvent poor drug retention into the tumor cells for efficient targeting. However, either the induction or inhibition of autophagy could have profound impacts on drug resistance reversal (Panzarini and Dini, 2014). One particular investigation in 2018 adopted hyaluronic acid-based nanoparticles for targeting tumor stem cells to decrease their drug resistance as a result of dormancy. In this work, the previously known antitumor agents (e.g., camptothecin, doxorubicin hydrochloride, or curcumin) were codelivered to malignant stem cells via four multilayered core-shell polymeric nanoparticles that were synthesized from different chitosan-modified polymers (Wang and He, 2018).

There is another hypothesis that argues the strict connection between inflammation and senescence, highlighting the role of chronic inflammation in awakening of dormant tumor cells (Manjili, 2017). Among cytokines, IFN- $\gamma$  has been shown to leave antitumorigenic effects that result in arresting of cell cycle and induction of dormancy in indolent tumor cells (Aqbi et al., 2018b). NMs featuring tailored chemical properties have been used for delivering IFN- $\gamma$  to tumor cells (Mejías

et al., 2011). Yet, the beneficial antitumor activity of this pleiotropic lymphokine might be autophagy-independent, since little has been reported regarding this matter. Most recently, scientists developed a novel chemo-immuno strategy toward targeted delivery of agents with high antitumor and/or antifibrotic potency, celastrol and mitoxantrone. In their study, mitoxantrone-responsive nanocarriers successfully curtailed the proliferation of tumor cells and further suppressed tumor invasion. The affected tumor cells remained dormant long after cotreatment with both agents, causing a sustained progression-free survival of the mice affected with desmoplastic melanoma (Liu et al., 2018a).

Nanocarriers were also used for the efficient delivery of dormancy-associated miRNAs to tumor cells. To this end, a group of scientists opted to prepare aminated polyglycerol dendritic nanocarriers for delivering miR-200c, miR-34a, and miR-93 into MG-63 and Saos-2 osteosarcoma tumor cells. Hence, using nanomaterial-mediated delivery of microRNAs associated with tumor-host interactions might be a useful strategy to induce a dormant-like state (Tiram et al., 2016).

### Autophagy Mediated Multiple Drug Resistance in Chemotherapy of Cancer Cells

Characterized by the gradual development of resistance to multiple chemotherapeutic agents with different mechanisms of action by tumor cells, multidrug resistance (MDR) is an undesirable outcome of chemotherapy that may occur in several instances (Holohan et al., 2013). A major culprit responsible for a significant proportion of cancer-associated mortality, MDR commonly results in the failure of treatment. A strikingly important challenge in cancer therapy, MDR, along with tumorigenesis, were previously thought to be correlated with disruptions in the regulation of autophagy. The idea came to fruition once several investigations reported potential involvement of autophagic pathways in the emergence of MDR (Kumar et al., 2012; Liu et al., 2020).

According to the recent findings, autophagy may affect MDR through a number of mechanisms, as explained below (Li et al., 2017):

1. Autophagy can prompt MDR as a cytoprotective mechanism (Table 4).
  - Autophagy is positively correlated with development of MDR.
  - Inhibition of autophagy may enhance the effectiveness of chemotherapy in cases with MDR.
2. Autophagy, when resulting in cell death, can overcome MDR (Table 4).
3. Autophagy triggers cell death in apoptosis-deficient MDR tumor cells.
4. Autophagy accelerates chemosensitization.

Induced by many cancer therapies, autophagy has been suggested to improve the survival of tumor cells and facilitate the development of MDR (Kondo et al., 2005; Amaravadi et al., 2011; Levy et al., 2017; Smith and Macleod 2019). For example, resistance to enzalutamide was counteracted by inhibition of autophagy in an investigation on prostate cancer (Nguyen et al., 2014). Likewise, in one study, inhibition of autophagy in estrogen receptor-positive breast cancer

resulted in sensitization of the resistant tumor cells to the cytotoxic effects of tamoxifen (Qadir et al., 2008; Samaddar et al., 2008). Autophagy was also reported to be activated in response to imatinib, used for the treatment of gastrointestinal stromal tumor. In this particular case, chloroquine (CQ) was adopted to overcome autophagy and trigger apoptosis in tumor cells (Gupta et al., 2010). A growing body of evidence suggests that autophagy is induced in response to many types of cancer therapy, hence the development of MDR (Galluzzi et al., 2017).

Disinhibition of autophagy is often suggested to be a consequence of low mTOR activity and is most commonly observed with therapies that target mTOR, PI3K, or AKT (Amaravadi et al., 2011). Nonetheless, one cannot certainly predict the induction of autophagy, since the extent of induction may vary in conventional and nonconventional therapies. An increased p53 activity triggered by DNA damage due to genotoxic therapeutics such as cisplatin may partly explain the undesirable induction of autophagy in conventional treatments that occur as a result of the increased activity of p53-dependent regulators of autophagy, e.g., DRAM1 (Crighton et al., 2006). Nevertheless, the exact role of p53 in this context is debatable, since this tumor-suppressing protein can also inhibit autophagy (Simon et al., 2017). Known to stimulate the activity of autophagy-regulating genes—namely, ATG5, LC3, etc.—the induction of ATF4 and forkhead box class O transcription factors due to ER stress response and overproduction of ROS, respectively, may explain the activation of autophagy in these instances (Ranganathan et al., 2006; Warr et al., 2013). The dual proapoptotic/antiapoptotic roles of autophagy largely depend on the characteristics of tumors. In the case of MDR cancer, exerts a protective effect on tumor cells by facilitating resistance to chemotherapeutic agents. Accordingly, inhibition of autophagy might be an effective strategy to sensitize MDR tumor cells to anticancer therapies. Nonetheless, more recent evidence suggests otherwise by pointing to the unappreciated potential of autophagy at sensitizing MDR tumor cells to anticancer agents and reversing MDR. Should this be the case, autophagy will inspire development of promising therapeutic modalities to overcome MDR (Li et al., 2017). Table 4 represents the studies on the prosurvival and prodeath role of autophagy in MDR of chemotherapy [updated from Li et al., (2017) and Das et al. (2019)].

### Conclusion and Outlook

As of this date, the exact molecular pathways involved in modulation of autophagy and their significance in tumor formation and progression are not clearly understood. However, as scientists suggest, autophagy is not an immutable constituent but rather a dynamic mechanism with quite varied behavior in cell biology. We ought to clarify that, because of the double-edged nature of autophagy, this regulatory mechanism can either result in induction or suppression of tumorigenesis depending on the type and stage of tumor. An increasing number of investigations have pointed to the impact of activated autophagy on the fate of tumor cells. From one point of view, autophagy might serve as an impeccable cellular shield against tumorigenesis, which can be adopted into therapeutic strategies. On the contrary, however, the exact same phenomenon might bring about further

TABLE 4

The studies on the prosurvival and prodeath role of autophagy in MDR of chemotherapy

Type of Cancer	Cell Line	Intervention/Drug	Methods or Molecular Mechanism to Study Autophagy	Ref
<b>a. The Prosurvival Role of Autophagy in MDR of Cancer</b>				
Gastric cancer	SGC7901 (Vincristine-resistant)	miR-23b-3p	siRNAs (Atg12, HMGB2), CQ	(An et al., 2015)
Esophageal cancer	Esophageal cancer cells (Drug-resistant)	5-FU	siRNAs (Beclin1, Atg7), 3-MA	(O'Donovan et al., 2011)
Breast cancer	MDA-MB-231 cells (Epirubicin-resistant)	Epirubicin	CQ	(Zhang et al., 2016)
	MCF-7 cells (Adriamycin-resistant)	Docetaxel	CQ	(Shi et al., 2015)
	MCF-7 cells (Adriamycin-resistant)	DOX	CQ	(Gao et al., 2017)
	MCF-7 cells (Adriamycin-resistant)	Capsaicin	P38 and ERK	(Choi et al., 2010)
	MDA-MB-231 cells	Trastuzumab	↑autophagic flux	(Vazquez-Martin et al., 2009)
	SKBR3 cells	Lapatinib, Gefitinib, Epirubicin, Trastuzumab	↑Atg12 transcripts	(Cufi et al., 2012)
	JIMT1 cells	Erlotinib, Trastuzumab	↑Bec1	(Sun et al., 2011a)
	MCF-7 cells	Anthracycline	↑LAPTM4B	(Li et al., 2011)
	BT549 cells	Tamoxifen	↑Atg5, Atg-7, and Bec1	(Qadir et al., 2008)
	MDA-MB-468 cells			
Prostate cancer	MCF-7 cells	Taxol group	mTOR pathway inhibition	(Notte et al., 2013)
	MDA-MB-231 cells	Carboplatin	↑ATG7 by HSF1	(Desai et al., 2013)
	MDA-MB-436 cells	Bortezomib	Autophagy induction through ATF4	(Milani et al., 2009)
	MCF-7 cells	DOX	eEF-2K induction	(Tekedereli et al., 2012)
	MDA-MB-231 cells	Ginsenoside F2	Atg7 elevation	(Mai et al., 2012)
	MCF-7 CSCs	Paclitaxel	↑autophagy,	(Wen et al., 2015)
	MDA-MB-231 cells		↑clearance of damaged mitochondria	
	MDA-MB-231 cells	Radiation	TAK1 activation	(Han et al., 2014)
	MCF-7 cells	CSTS203	↑Bec1 expression	(Wang et al., 2014a)
	PC3 cells (PTEN-deficient)	Ursolic acid	siRNAs (Atg5, Bec1), 3-MA	(Shin et al., 2012)
Ovarian cancer	PC3 cells	BITC	mTOR signaling inhibition	(Lin et al., 2013)
	Rv1 cells	Sulphoraphane	Mitochondria-derived ROS	(Naponelli et al., 2015)
	LNCaP cells,	Ursolic acid	Inhibition of Akt/mTOR pathway	(Shin et al., 2012)
	PC-3 cells	Piperlongumine	Inhibition of Akt/mTOR pathway through ROS	(Makhov et al., 2014)
	PC-3 cells	FTY720	Baf A1, siRNAs (Bec1, LC3)	(Zhang et al., 2010a)
	Ovarian cancer cells (Cisplatin-resistant)	Vincristine	CQ, 3-MA	(Liang et al., 2016)
	Ovarian carcinoma SKVOR (VCR-resistant)	VP-128	↓AKT/mTOR pathway	(Brasseur et al., 2013)
	A2780	Cisplatin	ERK pathway activation	(Wang and Wu 2014)
	RMG-1 cells,			
	OV90 cells,			
	OV433 cells,			
	OVC420 cells,			
	CAOV3 cells			

TABLE 4 continued

Type of Cancer	Cell Line	Intervention/Drug	Methods or Molecular Mechanism to Study Autophagy	Ref
Cervical Cancer	HeLa cells Hela cells Hela cells	TAW Paclitaxel Paclitaxel	↑Bcl1 ER stress-mediated Warburg effect-activated HIF1- α-mediated Baf A1, 3-MA, siRNA (Atg5) Atg5, ↓Bcl1	(Zhang et al., 2015) (Xu et al., 2015) (Peng et al., 2014) (Fan et al., 2010) (Luo et al., 2012)
Glioblastoma	Glioma cell lines (PTEN-deficient) U251MG cells	PI-103 Gambogic acid	PI3K/Akt/mTOR signaling inhibition AMPK activation, ↓PI3K/Akt pathway ↑(HIF-1α)/AMPK pathway	(Shen et al., 2013) (Yuan et al., 2014) (Hu et al., 2012)
	U87MG cells T98G cells U251 cells U87MG cells T98G cells U373 cells	ZD6474 Cucurbitacin I Bevacizumab		
	C6 glioma cells	Caffeic acid phenethyl ester	AMPK and MAPKs pathway phosphorylation ↑autophagy through Chloride channel-3 CQ	(Yu et al., 2011) (Su et al., 2013) (Carew et al., 2007)
	U251 cells CML cells (Imatinib-resistant)	Cisplatin SAHA		
	K562 cells K562 cells K562 cells, KU812 cells Nalm-6 cells Melanoma cells (B-Raf inhibitor-resistant)	Perifosine Daunorubicin Asparaginase Bortezomib B-raf inhibitors	↑Atg5 ERK activation Akt/mTOR and ERK	(Tong et al., 2012) (Han et al., 2011) (Song et al., 2015)
Melanoma	A549/DDP cells (Cisplatin-resistant)	Cisplatin	Bcl-2/Bcl1 complex disruption HCQ	(Wang et al., 2015b) (Ma et al., 2014)
Lung cancer	HCC827 cells, HCC4006 cells H23 cells, H1975 cells, A549 cells A549 cells	Gefitinib Erlotinib	3-MA ↑autophagic flux LC3A activation	(Ren et al., 2010) (Sakuma et al., 2013) (Nihira et al., 2014)
	H3122 cells A549 cells A549 cells 95D cells	Pterostilbene Crizotinib Paclitaxel Green tea extract Cucurbitacin E	ERK activation and both the AKT and JNK pathways inhibition AKT/mTOR pathways alteration ↓miR-17-5p ↑autophagic flux AKT/mTOR pathway regulation through ROS	(Hsieh et al., 2014) (Ji et al., 2014) (Chatterjee et al., 2014) (Izdebska et al., 2015) (Ma et al., 2016)
	A549 cells A549 cells DLD-1 cells, HT-29 cells, Colon26 cells	Radiation Cisplatin Adiponectin	↓ROS under hypoxia Hypoxia induction AMPKα and PPARα activation and of IGF-1/PI3K/Akt/mTOR pathway inhibition through Glucose deprivation Inhibition of Akt-mTOR signaling by ROS	(Chen et al., 2017) (Wu et al., 2015; Lee et al., 2015) (Habeeb et al., 2011)
	HCT116 cells, SW620 cells, C26 cells	Gambogic acid		(Zhang et al., 2014a)

TABLE 4 continued

Type of Cancer	Cell Line	Intervention/Drug	Methods or Molecular Mechanism to Study Autophagy	Ref
Hepatocellular carcinoma	SW480 cells	NVP-BEZ235 PLX4032	PI3K/mTOR signaling inhibition AMPK activation	(Yang et al., 2016) (Sueda et al., 2016)
	HT-29 cells, RKO cells, Caco-2 cells			
	HT-29 cells	Huh7, HCT116 Aspirin	AMPK/ULK1 signaling activation AMPK activation and mTOR inhibition independently	(Min et al., 2014) (Din et al., 2012)
	RKO cells, HCT116 cells, SW480 cells			
	Huh7 cells, HCT116 cells	Atorvastatin	Activation of p21 and ER stress via AMPK	(Makhov et al., 2014)
	MHCC97-L cells, PLC/PRF/5 cells, HepG2 cells	Sorafenib	↑IRE1 pathway through ER stress signaling	(Shi et al., 2011)
	Huh7 cells, SMMC-7721 cells	Oxaliplatin	ROS modulation	(Ding et al., 2011)
	HepG2 cells	Capsaicin	ROS-STAT3-mediated	(Chen et al., 2016)
	SMMC-7721 cells, HepG2 cells	Ionizing radiation	Atg4B induction by Egr-1	(Peng et al., 2017)
	PANC-1 cells, PaCa3 cells	Gemcitabine	Mutant p53 nuclear stabilization	(Fiorini et al., 2015)
Pancreatic cancer	PANC-1 cells	Bortezomib	AMPK-ULK1 signaling activation	(Min et al., 2014)
Head and neck cancer	PANC-1 CSCs	Gemcitabine	OPN/NF- $\kappa$ B signaling induction	(Yang et al., 2015)
	OE19 cells, OE21 cells, OE33 cells, KYSE450 cells	Cisplatin, 5-Fu	Bec1, Atg7-mediated	(O'Donovan et al., 2011)
	EC109 cells	Cisplatin	mTORC1 activity suppression	(Yu et al., 2014a)
	Hep-2 HSC-3 cells, Ca9-22 cells	Cisplatin Safingol	↓Bec1	(Kang et al., 2012) (Masui et al., 2016)
b. The Prodeath Role of Autophagy in MDR of Cancer				
Breast cancer	MCF-7 cells (Tamoxifen-resistant)	SAHA	3-MA	(Lee et al., 2012)
	MCF-7 cells (Adriamycin-resistant)	Isoliquiritigenin	CQ, 3-MA	(Wang et al., 2014b)
	MCF-7 cell lines (Apoptosis-resistant)	Hernandezine	3-MA, Atg7-knockout	(Law et al., 2016)
Colorectal cancer	MDA-MB-231 cells SW620 cells	LYN-1604 Tanshinones	Cell death modulated by ULK1 3-MA	(Zhang et al., 2017a) (Hu et al., 2015)
Leukemia	leukemic K562 cells (Edelfosine-resistant)	Edelfosine lipid NPs	Starvation, Staurosporine	(Azhar et al., 2014)
Lung cancer	lung cancer cells (Multidrug-resistant)	GMI protein	CQ	(Chiu et al., 2015)
	A549 cell lines (Apoptosis-resistant)	Hernandezine	3-MA, Atg7-knockout	(Law et al., 2016)
	H460 cells (Cisplatin-resistant)	Cisplatin	Trifluoperazine, 3-MA	(Sirichanchuen et al., 2012)

TABLE 4 continued

Type of Cancer	Cell Line	Intervention/Drug	Methods or Molecular Mechanism to Study Autophagy	Ref
	H460 cells (Apoptotic deficient)	RAD001	3-MA, siRNAs (Atg5, Bec1)	(Kim et al., 2008)
	H1299 cell lines (Apoptosis-resistant)	Hernandezine	Atg7-knockout, 3-MA	(Law et al., 2016)
	A549 cells, H1299 cells, H292 cells, H460 cells, HCC827 cells BEAS-2B	SBI0206965	Ulk1 inhibition	(Tang et al., 2017)
Bladder cancer	NCI-H1299 cells NCL-H460 cells (Cisplatin-resistant)	PS VII	Autophagy blocking by 3-MA via AMPK-ULK1	(Qian et al., 2020)
Ovarian cancer	SKVCR cells (Multidrug-resistant)	NVP-BEZ235	3-MA	(Li et al., 2013a)
	Ovarian cancer cells (Chemoresistant)	p53 plasmids	3-MA	(Kong et al., 2012)
	Hela cells (Apoptosis-resistant)	Quinacrine	Baf A1	(Khurana et al., 2015)
Cervical cancer	PC3 cells (Apoptosis-resistant)	Hernandezine	Atg7-knockout, 3-MA	(Law et al., 2016)
Prostate cancer	HepG2 cells (Apoptosis-resistant)	Hernandezine	Atg7-knockout, 3-MA	(Law et al., 2016)
Hepatocellular carcinoma	Hep3B cells (Apoptosis-resistant)	Hernandezine	Atg7-knockout, 3-MA	(Law et al., 2016)
	SGC7901 (Drug-resistant)	HTCC-MNPs	Atg7-knockout, 3-MA	(Li et al., 2016)

Baf A1, bafilomycin A1; Bec1, beclin 1; BITC, benzyl isothiocyanate; CML, chronic myelogenous leukemia; CSC, cancer stem cell; DOX, doxorubicin; Egr-1, early growth response factor; ERK, extracellular signal-regulated kinase; FTY720, 2-amino-2-[2-(4-octylphenyl)]-1,3-propanediol hydrochloride; 5-FU, 5-fluorouracil; GMI, ganoderma microsporium immunomodulatory; HCQ, hydroxychloroquine; HMGB2, high-mobility group box 2; HTCC-JNK, c-Jun N-terminal kinase; LAMP, lysosomal-associated membrane protein; LAPT4B, lysosomal-associated transmembrane protein; MNP, N-[(2-hydroxy-3-trimethylammonium propyl) chitosan chloride/alginate-encapsulated Fe3O4 magnetic nanoparticle; OPN, osteopontin; PP2, 4-amino-5-(4-chloro-phenyl)-7-(4-butyl)pyrazolo[3,4-d]pyrimidine; PS VII, Paris saponin VII; PTEN, phosphatase and tensin homolog; Rab, Ras-related protein; SAHA, suberoylamide hydroxamic acid; siRNA, small interfering RNA; TAK1, transforming growth factor-activated kinase 1; TAW, 8-p hydroxybenzoyl tovarol; TMZ, temozolomide; Ulk, UNC-51-like kinase; UPR, unfolded protein response; VCR, vincristine resistance; Vps, vacuolar protein sorting.

formation of tumors, with catastrophic consequences if provoked at will—namely, secondary metastasis and tumor relapse. Nevertheless, pharmacological modulation of autophagy has allegedly led to satisfactory results in limited research areas that could imply the potential of such interventions in development of novel therapeutics for cancer treatment. In this regard, scientists have less frequently discussed the potential effects of nanomaterials in mediation of autophagy.

Recently, newly emerging technologies have provided us with convenient methods for materialization of highly specialized nanoparticles for a variety of therapeutic purposes. Much to our dismay, however, the gross production of nanoparticles has led to an incontrovertible risk of exposure for people, prompting close studies of potentially harmful effects that might be conveyed through these tiny particles. Hopefully, an expansive array of information on the process of cellular uptake of nanoparticles has been gathered, indicating that the rate of cellular internalization is possible to be controlled based on physicochemical properties of nanoparticles, i.e., size, charge, and surface properties. It is anticipated that a thorough understanding of the functional interactions between autophagy and nanoparticles will tremendously impact the design of nanomaterials in such a way that development of tunable and safe nanomaterials will no longer be a far-fetched vision.

As for nanoparticles in this respect, several concerns still remain regarding the effect of different nanoparticles on the activation/suppression of autophagy, since it can very well lead to induction/inhibition of proliferation, differentiation, and invasiveness of tumor cells. According to many studies, nanomaterials can affect autophagy in malignant cells in such a way that can be adopted for development of therapeutic modalities for treatment of this malady. For instance, in a recent investigation (which is currently in press), we demonstrated the prominent role of gold nanoparticles applied through photothermal therapy in determining the destiny of tumor cells by means of regulating autophagy. In a similar fashion, in the present paper, we have sought to advise the scientists investigating in these particular fields of these concerns. That is to say, modulation of autophagy through nanomaterials is thought to be of therapeutic value for suppressing tumorigenesis in normal tissues and initiation of alternative cell death in compromised cells that struggle to properly kill themselves, on top of which stand malignant cells. This type of intervention can be further complemented by combining with traditional antitumor regimens to achieve a higher level of efficacy.

The complex interaction of autophagy-related pathways with the immune cells is another factor that might determine the fate of a tumor cell. Better understanding of the molecular pathways underlying the immune escape in recent years has accelerated the development of novel immunotherapies that aim to target molecules that would otherwise counteract the desirable antitumor immune response. Recent investigations have also highlighted the regulatory effects of autophagy on immunity through modulation of cytokine release and the function of immune cells. In return, a number of cytokines and certain types of immune cells reciprocate by affecting the autophagy itself. Accordingly, autophagy can very well be adopted for development of novel therapeutic

approaches when combined with tumor immunotherapy and even nanobiotechnology.

An increasing research interest in autophagy and autophagy-related cell death is evidence enough to the significance of this matter. Since the mechanism is of both physiologic and pathologic prominence, it would be best if autophagy were approached from both academic and clinical aspects. One crucial task in this field is to identify new biomarkers and develop novel tests to precisely determine the dynamic processes of autophagy in real-life samples. It is expected that such efforts will help us better understand how autophagy is modulated within tumor cells and ameliorate the design of clinical approaches aimed at targeting this mechanism. Prospective efforts should focus more on unraveling the genetic and physiologic grounds of autophagy, which would most likely improve the therapeutic value of our knowledge regarding this type of cell death.

#### Authorship Contributions

*Participated in research design:* Ghaznavi, Sheervalilou.

*Wrote or contributed to the writing of the manuscript:* Ghaznavi, Shirvaliloo, Zarebkohan, Shams, Radnia, Bahmanpour, Sargazi, Saravani, Shirvalilou, O. Shahraki, S. Shahraki, Nazarlou, Sheervalilou.

**Note Added in Proof:** The title of this article was changed from that used for the Fast Forward version published May 18, 2021.

#### References

- Abad Z, Beik J, Laurent S, Eslahi N, Khani T, Davani ES, Ghaznavi H, and Shakeri-Zadeh A (2019) Iron oxide-gold core-shell nano-theranostic for magnetically targeted photothermal therapy under magnetic resonance imaging guidance. *J Cancer Res Clin Oncol* **145**:1213–1219.
- Afzalipour R, Khoei S, Khoei S, Shirvalilou S, Jamali Raoufi N, Motevalian M, and Karimi MR (2019) Dual-targeting temozolomide loaded in folate-conjugated magnetic triblock copolymer nanoparticles to improve the therapeutic efficiency of rat brain gliomas. *ACS Biomater Sci Eng* **5**:6000–6011.
- Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. *Nat Rev Cancer* **7**:834–846.
- Amaravadi RK, Lippincott-Schwartz J, Yin X-M, Weiss WA, Takebe N, Timmer W, DiPaola RS, Lotze MT, and White E (2011) Principles and current strategies for targeting autophagy for cancer treatment. *Clin Cancer Res* **17**:654–666.
- An Y, Zhang Z, Shang Y, Jiang X, Dong J, Yu P, Nie Y, and Zhao Q (2015) miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2. *Cell Death Dis* **6**:e1766.
- Anding AL and Baehrecke EH (2017) Cleaning house: selective autophagy of organelles. *Dev Cell* **41**:10–22.
- Andreiff M (2003) Reviews in clinical and experimental hematology. *Rev Clin Exp Hematol* **7**:115–116.
- Apel A, Herr I, Schwarz H, Rodemann HP, and Mayer A (2008) Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. *Cancer Res* **68**:1485–1494.
- Aqbi HF, Tyutyunyk-Massey L, Keim RC, Butler SE, Thekkudan T, Joshi S, Smith TM, Bandyopadhyay D, Idowu MO, Bear HD, et al. (2018a) Autophagy-deficient breast cancer shows early tumor recurrence and escape from dormancy. *Oncotarget* **9**:22113–22122.
- Aqbi HF, Wallace M, Sappal S, Payne KK, and Manjili MH (2018b) IFN- $\gamma$  orchestrates tumor elimination, tumor dormancy, tumor escape, and progression. *J Leukoc Biol* **103**:1219–1223.
- Attar-Schneider O, Drucker L, and Gottfried M (2016) Migration and epithelial-to-mesenchymal transition of lung cancer can be targeted via translation initiation factors eIF4E and eIF4G1. *Lab Invest* **96**:1004–1015.
- Aznar MA, Lasa-Saracibar B, and Blanco-Prieto MJ (2014) Edelfosine lipid nanoparticles overcome multidrug resistance in K-562 leukemia cells by a caspase-independent mechanism. *Mol Pharm* **11**:2650–2658.
- Beik J, Khademi S, Attaran N, Sarkar S, Shakeri-Zadeh A, Ghaznavi H, and Ghadiri H (2017) A nanotechnology-based strategy to increase the efficiency of cancer diagnosis and therapy: folate-conjugated gold nanoparticles. *Curr Med Chem* **24**:4399–4416.
- Beik J, Khateri M, Khosravi Z, Kamrava SK, Kooranifar S, Ghaznavi H, and Shakeri-Zadeh A (2019) Gold nanoparticles in combinatorial cancer therapy strategies. *Coord Chem Rev* **387**:299–324.
- Blommaert EF, Luiken JJ, and Meijer AJ (1997) Autophagic proteolysis: control and specificity. *Histochem J* **29**:365–385.
- Brasseur K, Leblanc V, Fabi F, Parent S, Descôteaux C, Bérubé G, and Asselin E (2013) ER $\alpha$ -targeted therapy in ovarian cancer cells by a novel estradiol-platinum(II) hybrid. *Endocrinology* **154**:2281–2295.
- Kenzelmann Broz D, Spano Mello S, Biegling KT, Jiang D, Dusek RL, Brady CA, Sidow A, and Attardi LD (2013) Global genomic profiling reveals an extensive p53-

- regulated autophagy program contributing to key p53 responses. *Genes Dev* **27**:1016–1031.
- Burman C and Ktistakis NT (2010) Regulation of autophagy by phosphatidylinositol 3-phosphate. *FEBS Lett* **584**:1302–1312.
- Capparelli C, Guido C, Whitaker-Menezes D, Bonuccelli G, Balliet R, Pestell TG, Goldberg AF, Pestell RG, Howell A, Sneddon S, et al. (2012) Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis via glycolysis and ketone production. *Cell Cycle* **11**:2285–2302.
- Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, Houghton JA, Huang P, Giles FJ, and Cleveland JL (2007) Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. *Blood* **110**:313–322.
- Catalano M, D'Alessandro G, Lepore F, Corazzari M, Caldarella S, Valacca C, Faienza F, Esposito V, Limatola C, Ceconi F, et al. (2015) Autophagy induction impairs migration and invasion by reversing EMT in glioblastoma cells. *Mol Oncol* **9**:1612–1625.
- Changizi O, Khoei S, Mahdavian A, Shirvalilou S, Mahdavi SR, and Keyvan Rad J (2020) Enhanced radiosensitivity of LNCaP prostate cancer cell line by gold-photoactive nanoparticles modified with folic acid. *Photodiagn Photodyn Ther* **29**:101602.
- Chao C, Herr D, Chun J, and Xu Y (2006) Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. *EMBO J* **25**:2615–2622.
- Chatterjee A, Chattopadhyay D, and Chakrabarti G (2014) miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression. *PLoS One* **9**:e95716.
- Chen C-Y, Chen J, He L, and Stiles BL (2018a) PTEN: tumor suppressor and metabolic regulator. *Front Endocrinol (Lausanne)* **9**:338.
- Chen N, Han Y, Luo Y, Zhou Y, Hu X, Yu Y, Xie X, Yin M, Sun J, and Zhong W (2018b) Nanodiamond-based non-canonical autophagy inhibitor synergistically induces cell death in oxygen-deprived tumors. *Mater Horiz* **5**:1204–1210.
- Chen N and Karantza-Wadsworth V (2009) Role and regulation of autophagy in cancer. *Biochim Biophys Acta* **1793**:1516–1523.
- Chen X, Tan M, Xie Z, Feng B, Zhao Z, Yang K, Hu C, Liao N, Wang T, Chen D, et al. (2016) Inhibiting ROS-STAT3-dependent autophagy enhanced capsaicin-induced apoptosis in human hepatocellular carcinoma cells. *Free Radic Res* **50**:744–755.
- Chen X, Wang P, Guo F, Wang X, Wang J, Xu J, Yuan D, Zhang J, and Shao C (2017) Autophagy enhanced the radioresistance of non-small cell lung cancer by regulating ROS level under hypoxia condition. *Int J Radiat Biol* **93**:764–770.
- Chen Y, Yang L, Feng C, and Wen L-P (2005) Nano neodymium oxide induces massive vacuolization and autophagic cell death in non-small cell lung cancer NCI-H460 cells. *Biochem Biophys Res Commun* **337**:52–60.
- Cheong H (2015) Integrating autophagy and metabolism in cancer. *Arch Pharm Res* **38**:358–371.
- Chiu L-Y, Hu M-E, Yang T-Y, Hsin I-L, Ko J-L, Tsai K-J, and Sheu G-T (2015) Immunomodulatory protein from *Ganoderma microsporum* induces pro-death autophagy through Akt-mTOR-p70S6K pathway inhibition in multidrug resistant lung cancer cells. *PLoS One* **10**:e0125774.
- Choi AM, Ryter SW, and Levine B (2013) Autophagy in human health and disease. *N Engl J Med* **368**:651–662.
- Choi C-H, Jung Y-K, and Oh S-H (2010) Autophagy induction by capsaicin in malignant human breast cells is modulated by p38 and extracellular signal-regulated mitogen-activated protein kinases and retards cell death by suppressing endoplasmic reticulum stress-mediated apoptosis. *Mol Pharmacol* **78**:114–125.
- Choi KS (2012) Autophagy and cancer. *Exp Mol Med* **44**:109–120.
- Cordani M and Somoza A (2019) Targeting autophagy using metallic nanoparticles: a promising strategy for cancer treatment. *Cell Mol Life Sci* **76**:1215–1242.
- Crichton D, Wilkinson S, O'Prey J, Syed N, Smith P, Harrison PR, Gasco M, Garrone O, Crook T, and Ryan KM (2006) DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. *Cell* **126**:121–134.
- Criollo A, Dessen P, and Kroemer G (2009) DRAM: a phylogenetically ancient regulator of autophagy. *Cell Cycle* **8**:2319–2320.
- Cubillos-Ruiz JR, Bettigole SE, and Glimcher LH (2017) Tumorigenic and immunosuppressive effects of endoplasmic reticulum stress in cancer. *Cell* **168**:692–706.
- Cuñi S, Vazquez-Martin A, Oliveras-Ferreras C, Corominas-Faja B, Urruticoechea A, Martin-Castillo B, and Menendez JA (2012) Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment. *Oncotarget* **3**:1600–1614.
- Cusan M, Mungo G, De Marco Zompit M, Segatto I, Belletti B, and Baldassarre G (2018) Landscape of CDKN1B mutations in luminal breast cancer and other hormone-driven human tumors. *Front Endocrinol (Lausanne)* **9**:393.
- Das CK, Banerjee I, and Mandal M (2019) Pro-survival autophagy: an emerging candidate of tumor progression through maintaining hallmarks of cancer. *Semin Cancer Biol* **66**:59–74.
- Desai S, Liu Z, Yao J, Patel N, Chen J, Wu Y, Ahn EE-Y, Fodstad O, and Tan M (2013) Heat shock factor 1 (HSF1) controls chemoresistance and autophagy through transcriptional regulation of autophagy-related protein 7 (ATG7). *J Biol Chem* **288**:9165–9176.
- Diaz-Troya S, Pérez-Pérez ME, Florencio FJ, and Crespo JL (2008) The role of TOR in autophagy regulation from yeast to plants and mammals. *Autophagy* **4**:851–865.
- Dikic I, Johansen T, and Kirkin V (2010) Selective autophagy in cancer development and therapy. *Cancer Res* **70**:3431–3434.
- Dimco G, Knight RA, Latchman DS, and Stephanou A (2010) STAT1 interacts directly with cyclin D1/Cdk4 and mediates cell cycle arrest. *Cell Cycle* **9**:4638–4649.
- Din FV, Valanciute A, Houde VP, Zibrova D, Green KA, Sakamoto K, Alessi DR, and Dunlop MG (2012) Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. *Gastroenterology* **142**:1504–1515.
- Ding Z-B, Hui B, Shi Y-H, Zhou J, Peng Y-F, Gu C-Y, Yang H, Shi G-M, Ke A-W, Wang X-Y, et al. (2011) Autophagy activation in hepatocellular carcinoma contributes to the tolerance of oxaliplatin via reactive oxygen species modulation. *Clin Cancer Res* **17**:6229–6238.
- El Andaloussi A, Habib S, Soylemes G, Laknaur A, Elhusseini H, Al-Hendy A, and Ismail N (2017) Defective expression of ATG4D abrogates autophagy and promotes growth in human uterine fibroids. *Cell Death Dis* **3**:1–9.
- Eom H-J and Choi J (2010) p38 MAPK activation, DNA damage, cell cycle arrest and apoptosis as mechanisms of toxicity of silver nanoparticles in Jurkat T cells. *Environ Sci Technol* **44**:8337–8342.
- Eskelinen E-L (2011) The dual role of autophagy in cancer. *Curr Opin Pharmacol* **11**:294–300.
- Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, Nicolaides T, Haas-Kogan D, James CD, Oakes SA, Debnath J, et al. (2010) Akt and autophagy cooperate to promote survival of drug-resistant glioma. *Sci Signal* **3**:ra81.
- Fernández AF and López-Otín C (2015) The functional and pathologic relevance of autophagy proteases. *J Clin Invest* **125**:33–41.
- Fiaschi T and Chiarugi P (2012) Oxidative stress, tumor microenvironment, and metabolic reprogramming: a diabolic liaison. *Int J Cell Biol* **2012**:762825.
- Fiorini C, Cordani M, Padroni C, Blandino G, Di Agostino S, and Donadelli M (2015) Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine. *Biochim Biophys Acta* **1853**:89–100.
- La Belle Flynn A, Calhoun BC, Sharma A, Chang JC, Almasan A, and Schiemann WP (2019) Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression. *Nat Commun* **10**:3668.
- Fulda S, Gorman AM, Hori O, and Samali A (2010) Cellular stress responses: cell survival and cell death. *Int J Cell Biol* **2010**:214074.
- Galluzzi L, Bravo-San Pedro JM, Levine B, Green DR, and Kroemer G (2017) Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. *Nat Rev Drug Discov* **16**:487–511.
- Gao M, Xu Y, and Qiu L (2017) Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition. *J Liposome Res* **27**:151–160.
- Gewirtz DA (2009) Autophagy, senescence and tumor dormancy in cancer therapy. *Autophagy* **5**:1232–1234.
- Ghavami S, Shojaei S, Yeganeh B, Ande SR, Jangamreddy JR, Mehrpour M, Christofferson J, Chaabane W, Moghadam AR, Kashani HH, et al. (2014) Autophagy and apoptosis dysfunction in neurodegenerative disorders. *Prog Neurobiol* **112**:24–49.
- Ghaznavi H, Hosseini-Nami S, Kamrava SK, Irajirad R, Maleki S, Shakeri-Zadeh A, and Montazerabadi A (2018) Folic acid conjugated PEG coated gold-iron oxide core-shell nanocomplex as a potential agent for targeted photothermal therapy of cancer. *Artif Cells Nanomed Biotechnol* **46**:1594–1604.
- Gong C, Bauvy C, Tonelli G, Yue W, Deloménie C, Nicolas V, Zhu Y, Domergue V, Marin-Esteban V, Tharinger H, et al. (2013) Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/progenitor cells. *Oncogene* **32**:2261–2272, 1–11.
- Gozuacik D and Kimchi A (2004) Autophagy as a cell death and tumor suppressor mechanism. *Oncogene* **23**:2891–2906.
- Gundara JS, Zhao J, Robinson BG, and Sidhu SB (2012) Oncophagy: harnessing regulation of autophagy in cancer therapy. *Endocr Relat Cancer* **19**:R281–R295.
- Guo JY, Teng X, Laddha SV, Ma S, Van Nostrand SC, Yang Y, Khor S, Chan CS, Rabinowitz JD, and White E (2016) Autophagy provides metabolic substrates to maintain energy charge and nucleotide pools in Ras-driven lung cancer cells. *Genes Dev* **30**:1704–1717.
- Gupta A, Roy S, Lazar AJ, Wang W-L, McAuliffe JC, Reynoso D, McMahon J, Taguchi T, Floris G, Debiec-Rychter M, et al. (2010) Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). *Proc Natl Acad Sci USA* **107**:14333–14338.
- Habeeb BS, Kitayama J, and Nagawa H (2011) Adiponectin supports cell survival in glucose deprivation through enhancement of autophagic response in colorectal cancer cells. *Cancer Sci* **102**:999–1006.
- Han MW, Lee JC, Choi J-Y, Kim GC, Chang HW, Nam HY, Kim SW, and Kim SY (2014) Autophagy inhibition can overcome radioresistance in breast cancer cells through suppression of TAK1 activation. *Anticancer Res* **34**:1449–1455.
- Han W, Sun J, Feng L, Wang K, Li D, Pan Q, Chen Y, Jin W, Wang X, Pan H, et al. (2011) Autophagy inhibition enhances daunorubicin-induced apoptosis in K562 cells. *PLoS One* **6**:e28491.
- Holohan C, Van Schaeuybroeck S, Longley DB, and Johnston PG (2013) Cancer drug resistance: an evolving paradigm. *Nat Rev Cancer* **13**:714–726.
- Hönscheid P, Datta K, and Muders MH (2014) Autophagy: detection, regulation and its role in cancer and therapy response. *Int J Radiat Biol* **90**:628–635.
- Hoyer-Hansen M and Jäättelä M (2008) Autophagy: an emerging target for cancer therapy. *Autophagy* **4**:574–580.
- Hsieh M-J, Lin C-W, Yang S-F, Sheu G-T, Yu Y-Y, Chen M-K, and Chiou H-L (2014) A combination of pterostilbene with autophagy inhibitors exerts efficient apoptotic characteristics in both chemosensitive and chemoresistant lung cancer cells. *Toxicol Sci* **137**:65–75.
- Hu T, Wang L, Zhang L, Lu L, Shen J, Chan RL, Li M, Wu WK, To KK, and Cho CH (2015) Sensitivity of apoptosis-resistant colon cancer cells to tanshinones is mediated by autophagic cell death and p53-independent cytotoxicity. *Phytomedicine* **22**:536–544.
- Hu Y-L, DeLay M, Jahangiri A, Molinaro AM, Rose SD, Carbonell WS, and Aghi MK (2012) Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. *Cancer Res* **72**:1773–1783.
- Hu Y, Zhang H-R, Dong L, Xu M-R, Zhang L, Ding W-P, Zhang J-Q, Lin J, Zhang Y-J, Qiu B-S, et al. (2019) Enhancing tumor chemotherapy and overcoming drug resistance through autophagy-mediated intracellular dissolution of zinc oxide nanoparticles. *Nanoscale* **11**:11789–11807.
- Huang W-W, Tsai S-C, Peng S-F, Lin M-W, Chiang J-H, Chiu Y-J, Fushiya S, Tseng MT, and Yang J-S (2013) Kaempferol induces autophagy through AMPK and AKT signaling molecules and causes G2/M arrest via downregulation of CDK1/cyclin B in SK-HEP-1 human hepatic cancer cells. *Int J Oncol* **42**:2069–2077.

- Hurley JH and Young LN (2017) Mechanisms of autophagy initiation. *Annu Rev Biochem* **86**:225–244.
- Hussain S, Al-Nsour F, Rice AB, Marshburn J, Yingling B, Ji Z, Zink JJ, Walker NJ, and Garantzotis S (2012) Cerium dioxide nanoparticles induce apoptosis and autophagy in human peripheral blood monocytes. *ACS Nano* **6**:5820–5829.
- Izdebska M, Klimaszewska-Wisniewska A, Halas M, Gagat M, and Grzanka A (2015) Green tea extract induces protective autophagy in A549 non-small lung cancer cell line. *Postepy Hig Med Dosw (Online)* **69**:1478–1484.
- Ji C, Zhang L, Cheng Y, Patel R, Wu H, Zhang Y, Wang M, Ji S, Belani CP, Yang J-M, et al. (2014) Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer. *Cancer Biol Ther* **15**:570–577.
- Jiang G-M, Tan Y, Wang H, Peng L, Chen H-T, Meng X-J, Li L-L, Liu Y, Li W-F, and Shan H (2019) The relationship between autophagy and the immune system and its applications for tumor immunotherapy. *Mol Cancer* **18**:17.
- Jing K, Song K-S, Shin S, Kim N, Jeong S, Oh H-R, Park J-H, Seo K-S, Heo J-Y, Han J, et al. (2011) Docosahexaenoic acid induces autophagy through p53/AMPK/mTOR signaling and promotes apoptosis in human cancer cells harboring wild-type p53. *Autophagy* **7**:1348–1358.
- Kamada Y, Funakoshi T, Shintani T, Nagano K, Ohsumi M, and Ohsumi Y (2000) Tor-mediated induction of autophagy via an Apg1 protein kinase complex. *J Cell Biol* **150**:1507–1513.
- Kang MH and Reynolds CP (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. *Clin Cancer Res* **15**:1126–1132.
- Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Kim SS, Ahn CH, Yoo NJ, and Lee SH (2009) Frameshift mutations of autophagy-related genes ATG2B, ATG5, ATG9B and ATG12 in gastric and colorectal cancers with microsatellite instability. *J Pathol* **217**:702–706.
- Kang R, Wang Z-H, Wang B-Q, Zhang C-M, Gao W, Feng Y, Bai T, Zhang H-L, Huang-Pu H, and Wen S-X (2012) Inhibition of autophagy-potentiated chemosensitivity to cisplatin in laryngeal cancer Hep-2 cells. *Am J Otolaryngol* **33**:678–684.
- Kang R, Zeh HJ, Lotze MT, and Tang D (2011) The Beclin 1 network regulates autophagy and apoptosis. *Cell Death Differ* **18**:571–580.
- Kao C, Chao A, Tsai CL, Chuang WC, Huang WP, Chen GC, Lin CY, Wang TH, Wang HS, and Lai CH (2014) Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation. *Cell Death Dis* **5**:e1510–e1510.
- Karantz-Wadsworth V and White E (2007) Role of autophagy in breast cancer. *Autophagy* **3**:610–613.
- Karch J, Schips TG, Maliken BD, Brody MJ, Sargent MA, Kanisick O, and Molken JD (2017) Autophagic cell death is dependent on lysosomal membrane permeability through Bax and Bak. *eLife* **6**:e30543.
- Khan MI, Mohammad A, Patil G, Naqvi SA, Chauhan LK, and Ahmad I (2012) Induction of ROS, mitochondrial damage and autophagy in lung epithelial cancer cells by iron oxide nanoparticles. *Biomaterials* **33**:1477–1488.
- Khurana A, Roy D, Kalogera E, Mondal S, Wen X, He X, Dowdy S, and Shridhar V (2015) Quinacrine promotes autophagic cell death and chemosensitivity in ovarian cancer and attenuates tumor growth. *Oncotarget* **6**:36354–36369.
- Kim KW, Hwang M, Moretti L, Jaboin JJ, Cha YI, and Lu B (2008) Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer. *Autophagy* **4**:659–668.
- Kimmelman AC (2011) The dynamic nature of autophagy in cancer. *Genes Dev* **25**:1999–2010.
- King KY, Baldrige MT, Weksberg DC, Chambers SM, Lukov GL, Wu S, Boles NC, Jung SY, Qin J, Liu D, et al. (2011) Irfm1 protects hematopoietic stem cells by negative regulation of IFN signaling. *Blood* **118**:1525–1533.
- Kirisako T, Baba M, Ishihara N, Miyazawa K, Ohsumi M, Yoshimori T, Noda T, and Ohsumi Y (1999) Formation process of autophagosome is traced with Apg8/Aut7p in yeast. *J Cell Biol* **147**:435–446.
- Kondo Y, Kanzawa T, Sawaya R, and Kondo S (2005) The role of autophagy in cancer development and response to therapy. *Nat Rev Cancer* **5**:726–734.
- Kondo Y and Kondo S (2006) Autophagy and cancer therapy. *Autophagy* **2**:85–90.
- Kong D, Ma S, Liang B, Yi H, Zhao Y, Xin R, Cui L, Jia L, Liu X, and Liu X (2012) The different regulatory effects of p53 status on multidrug resistance are determined by autophagy in ovarian cancer cells. *Biomed Pharmacother* **66**:271–278.
- Kumar P, Zhang D-M, Degenhardt K, and Chen Z-S (2012) Autophagy and transporter-based multi-drug resistance. *Cells* **1**:558–575.
- Law BYK, Mok SWF, Chan WK, Xu SW, Wu AG, Yao XJ, Wang JR, Liu L, and Wong VKW (2016) Hernandezine, a novel AMPK activator induces autophagic cell death in drug-resistant cancers. *Oncotarget* **7**:8090–8104.
- Lee JG, Shin JH, Shim HS, Lee CY, Kim DJ, Kim YS, and Chung KY (2015) Autophagy contributes to the chemoresistance of non-small cell lung cancer in hypoxic conditions. *Respir Res* **16**:138.
- Lee YJ, Won AJ, Lee J, Jung JH, Yoon S, Lee BM, and Kim HS (2012) Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells. *Int J Med Sci* **9**:881–893.
- Levine B (2007) Cell biology: autophagy and cancer. *Nature* **446**:745–747.
- Levine B and Kroemer G (2008) Autophagy in the pathogenesis of disease. *Cell* **132**:27–42.
- Levy JMM, Towers CG, and Thorburn A (2017) Targeting autophagy in cancer. *Nat Rev Cancer* **17**:528–542.
- Li C, Liu H, Sun Y, Wang H, Guo F, Rao S, Deng J, Zhang Y, Miao Y, Guo C, et al. (2009) PAMAM nanoparticles promote acute lung injury by inducing autophagic cell death through the Akt-TSC2-mTOR signaling pathway. *J Mol Cell Biol* **1**:37–45.
- Li JR, Cheng C-L, Yang C-R, Ou Y-C, Wu M-J, and Ko J-L (2013a) Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux. *Toxicol Lett* **220**:267–276.
- Li L, Chen Y, and Gibson SB (2013b) Starvation-induced autophagy is regulated by mitochondrial reactive oxygen species leading to AMPK activation. *Cell Signal* **25**:50–65.
- Liu L, Yan L, Liao N, Wu W-Q, and Shi J-L (2020) A Review of ULK1-Mediated Autophagy in Drug Resistance of Cancer. *Cancers (Basel)* **12**:1–23.
- Li X, Feng J, Zhang R, Wang J, Su T, Tian Z, Han D, Zhao C, Fan M, Li C, et al. (2016) Quaternized chitosan/alginate-Fe3O4 magnetic nanoparticles enhance the chemosensitization of multidrug-resistant gastric carcinoma by regulating cell autophagy activity in mice. *J Biomed Nanotechnol* **12**:948–961.
- Li X, He S, and Ma B (2020) Autophagy and autophagy-related proteins in cancer. *Mol Cancer* **19**:12.
- Li Y-J, Lei Y-H, Yao N, Wang C-R, Hu N, Ye W-C, Zhang D-M, and Chen Z-S (2017) Autophagy and multidrug resistance in cancer. *Chin J Cancer* **36**:52.
- Li Y, Zhang Q, Tian R, Wang Q, Zhao JJ, Iglehart JD, Wang ZC, and Richardson AL (2011) Lysosomal transmembrane protein LAPTM4B promotes autophagy and tolerance to metabolic stress in cancer cells. *Cancer Res* **71**:7481–7489.
- Liang B, Liu X, Liu Y, Kong D, Liu X, Zhong R, and Ma S (2016) Inhibition of autophagy sensitizes MDR-phenotype ovarian cancer SKVCR cells to chemotherapy. *Biomed Pharmacother* **82**:98–105.
- Liang C (2010) Negative regulation of autophagy. *Cell Death Differ* **17**:1807–1815.
- Liang C, Feng P, Ku B, Dotan I, Canaan D, Oh B-H, and Jung JU (2006) Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG. *Nat Cell Biol* **8**:688–699.
- Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, and Levine B (1999) Induction of autophagy and inhibition of tumorigenesis by beclin 1. *Nature* **402**:672–676.
- Lin J-F, Tsai T-F, Liao P-C, Lin Y-H, Lin Y-C, Chen H-E, Chou K-Y, and Hwang TI-S (2013) Benzyl isothiocyanate induces protective autophagy in human prostate cancer cells via inhibition of mTOR signaling. *Carcinogenesis* **34**:406–414.
- Lindqvist LM and Vaux DL (2014) BCL2 and related prosurvival proteins require BAK1 and BAX to affect autophagy. *Autophagy* **10**:1474–1475.
- Liu HL, Zhang YL, Yang N, Zhang YX, Liu XQ, Li CG, Zhao Y, Wang YG, Zhang GG, Yang P, et al. (2011) A functionalized single-walled carbon nanotube-induced autophagic cell death in human lung cells through Akt-TSC2-mTOR signaling. *Cell Death Dis* **2**:e159.
- Liu Q, Chen F, Hou L, Shen L, Zhang X, Wang D, and Huang L (2018a) Nanocarrier-mediated chemo-immunotherapy arrested cancer progression and induced tumor dormancy in desmoplastic melanoma. *ACS Nano* **12**:7812–7825.
- Liu Y, Lv J, and Huang B (2018b) Mediating the death of dormant tumor cells. *Mol Cell Oncol* **5**:e1458013.
- Liu Y, Lv J, Liu J, Liang X, Jin X, Xie J, Zhang L, Chen D, Fiskesund R, Tang K, et al. (2018c) STAT3/p53 pathway activation disrupts IFN- $\beta$ -induced dormancy in tumor-repopulating cells. *J Clin Invest* **128**:1057–1073.
- Lu H-Y, Chang Y-J, Fan N-C, Wang L-S, Lai N-C, Yang C-M, Wu L-C, and Ho JA (2015) Synergism through combination of chemotherapy and oxidative stress-induced autophagy in A549 lung cancer cells using redox-responsive nanohybrids: a new strategy for cancer therapy. *Biomaterials* **42**:30–41.
- Luo G-X, Cai J, Lin J-Z, Luo W-S, Luo H-S, Jiang Y-Y, and Zhang Y (2012) Autophagy inhibition promotes gambogic acid-induced suppression of growth and apoptosis in glioblastoma cells. *Asian Pac J Cancer Prev* **13**:6211–6216.
- Lv Q, Hua F, and Hu Z-W (2012) DEDD, a novel tumor repressor, reverses epithelial-mesenchymal transition by activating selective autophagy. *Autophagy* **8**:1675–1676.
- Ma G, Luo W, Lu J, Ma D-L, Leung C-H, Wang Y, and Chen X (2016) Cucurbitacin E induces caspase-dependent apoptosis and protective autophagy mediated by ROS in lung cancer cells. *Chem Biol Interact* **253**:1–9.
- Ma X-H, Piao S-F, Dey S, McAfee Q, Karakousis G, Villanueva J, Hart LS, Levi S, Hu J, Zhang G, et al. (2014) Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. *J Clin Invest* **124**:1406–1417.
- Maes H, Kuchnio A, Peric A, Moens S, Nys K, De Bock K, Quaegebeur A, Schoors S, Georgiadou M, Wouters J, et al. (2014) Tumor vessel normalization by chloroquine independent of autophagy. *Cancer Cell* **26**:190–206.
- Maes H, Rubio N, Garg AD, and Agostinis P (2013) Autophagy: shaping the tumor microenvironment and therapeutic response. *Trends Mol Med* **19**:428–446.
- Mai TT, Moon J, Song Y, Viet PQ, Phuc PV, Lee JM, Yi T-H, Cho M, and Cho SK (2012) Ginsenoside F2 induces apoptosis accompanied by protective autophagy in breast cancer stem cells. *Cancer Lett* **321**:144–153.
- Makhov P, Golovine K, Teper E, Kutikov A, Mehrazin R, Corcoran A, Tulin A, Uzzo RG, and Kolenko VM (2014) Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death. *Br J Cancer* **110**:899–907.
- Manjili MH (2017) Tumor dormancy and relapse: from a natural byproduct of evolution to a disease state. *Cancer Res* **77**:2564–2569.
- Maryyama T and Noda NN (2017) Autophagy-regulating protease Atg4: structure, function, regulation and inhibition. *J Antibiot (Tokyo)* **71**:72–78.
- Masui A, Hamada M, Kameyama H, Wakabayashi K, Takasu A, Imai T, Iwai S, and Yura Y (2016) Autophagy as a survival mechanism for squamous cell carcinoma cells in endonuclease G-mediated apoptosis. *PLoS One* **11**:e0162786.
- Mathew R, Karantz-Wadsworth V, and White E (2007) Role of autophagy in cancer. *Nat Rev Cancer* **7**:961–967.
- Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen H-Y, Bray K, Reddy A, Bhanot G, Gelinas C, et al. (2009) Autophagy suppresses tumorigenesis through elimination of p62. *Cell* **137**:1062–1075.
- Mei L, Zhang X, and Feng S-S (2014) Autophagy inhibition strategy for advanced nanomedicine. *Nanomedicine (Lond)* **9**:377–380.
- Mejias R, Pérez-Yagüe S, Gutiérrez L, Cabrera LI, Spada R, Acedo P, Serna CJ, Lázaro FJ, Villanueva A, Morales MdP, et al. (2011) Dimercaptosuccinic acid-coated magnetite nanoparticles for magnetically guided in vivo delivery of interferon gamma for cancer immunotherapy. *Biomaterials* **32**:2938–2952.
- Milani M, Rzymiski T, Mellor HR, Pike L, Bottini A, Generali D, and Harris AL (2009) The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. *Cancer Res* **69**:4415–4423.

- Min H, Xu M, Chen ZR, Zhou JD, Huang M, Zheng K, and Zou XP (2014) Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells. *Cancer Chemother Pharmacol* **74**:167–176.
- Mirrahimi M, Abed Z, Beik J, Shiri I, Shiralizadeh Dezfouli A, Mahabadi VP, Kamran Kamrava S, Ghaznavi H, and Shakeri-Zadeh A (2019) A thermo-responsive alginate nanogel platform co-loaded with gold nanoparticles and cisplatin for combined cancer chemo-photothermal therapy. *Pharmacol Res* **143**:178–185.
- Mizushima N and Komatsu M (2011) Autophagy: renovation of cells and tissues. *Cell* **147**:728–741.
- Mizushima N, Noda T, Yoshimori T, Tanaka Y, Ishii T, George MD, Klionsky DJ, Ohsumi M, and Ohsumi Y (1998) A protein conjugation system essential for autophagy. *Nature* **395**:395–398.
- Mizushima N, Yamamoto A, Hatano M, Kobayashi Y, Kabeya Y, Suzuki K, Tokuhisa T, Ohsumi Y, and Yoshimori T (2001) Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells. *J Cell Biol* **152**:657–668.
- Murthy A, Li Y, Peng I, Reichelt M, Katakam AK, Noubade R, Roose-Girma M, DeVoss J, Diehl L, Graham RR, et al. (2014) A Crohn's disease variant in Atg16l1 enhances its degradation by caspase 3. *Nature* **506**:456–462.
- Nagata S (2018) Apoptosis and clearance of apoptotic cells. *Annu Rev Immunol* **36**:489–517.
- Naponelli V, Modernelli A, Bettuzzi S, and Rizzi F (2015) Roles of autophagy induced by natural compounds in prostate cancer. *BioMed Res Int* **2015**:121826.
- Nguyen HG, Yang JC, Kung H-J, Shi XB, Tilki D, Lara Jr PN, DeVere White RW, Gao AC, and Evans CP (2014) Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. *Oncogene* **33**:4521–4530.
- Ni H-M, Woolbright BL, Williams J, Copple B, Cui W, Luyendyk JP, Jaeschke H, and Ding W-X (2014) Nr1f2 promotes the development of fibrosis and tumorigenesis in mice with defective hepatic autophagy. *J Hepatol* **61**:617–625.
- Nihira K, Miki Y, Iida S, Narumi S, Ono K, Iwabuchi E, Ise K, Mori K, Saito M, Ebina M, et al. (2014) An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma. *J Pathol* **234**:277–288.
- Nishida K, Yamaguchi O, and Otsu K (2008) Crosstalk between autophagy and apoptosis in heart disease. *Circ Res* **103**:343–351.
- Noman MZ, Janji B, Kaminska B, Van Moer K, Pierson S, Przanowski P, Buart S, Berchem G, Romero P, Mami-Chouaib F, et al. (2011) Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. *Cancer Res* **71**:5976–5986.
- Notte A, Ninane N, Arnould T, and Michiels C (2013) Hypoxia counteracts taxol-induced apoptosis in MDA-MB-231 breast cancer cells: role of autophagy and JNK activation. *Cell Death Dis* **4**:e638.
- O'Donovan TR, O'Sullivan GC, and McKenna SL (2011) Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics. *Autophagy* **7**:509–524.
- Panzarini E and Dini L (2014) Nanomaterial-induced autophagy: a new reversal MDR tool in cancer therapy? *Mol Pharm* **11**:2527–2538.
- Peng WX, Wan YY, Gong AH, Ge L, Jin J, Xu M, and Wu CY (2017) Egr-1 regulates irradiation-induced autophagy through Atg4B to promote radioresistance in hepatocellular carcinoma cells. *Oncogenesis* **6**:e292.
- Peng X, Gong F, Chen Y, Jiang Y, Liu J, Yu M, Zhang S, Wang M, Xiao G, and Liao H (2014) Autophagy promotes paclitaxel resistance of cervical cancer cells: involvement of Warburg effect activated hypoxia-induced factor 1- $\alpha$ -mediated signaling. *Cell Death Dis* **5**:e1367.
- Petiot A, Ogier-Denis E, Blommaert EF, Meijer AJ, and Codogno P (2000) Distinct classes of phosphatidylinositol 3'-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells. *J Biol Chem* **275**:992–998.
- Poillet-Perez L, Despouy G, Delage-Mourroux R, and Boyer-Guittaut M (2015) Interplay between ROS and autophagy in cancer cells, from tumor initiation to cancer therapy. *Redox Biol* **4**:184–192.
- Polewska J, Skwarska A, Augustin E, and Konopa J (2013) DNA-damaging imidazoacridinone C-1311 induces autophagy followed by irreversible growth arrest and senescence in human lung cancer cells. *J Pharmacol Exp Ther* **346**:393–405.
- Popp L and Segatori L (2015) Differential autophagic responses to nano-sized materials. *Curr Opin Biotechnol* **36**:129–136.
- Qadir MA, Kwok B, Dragowska WH, To KH, Le D, Bally MB, and Gorski SM (2008) Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization. *Breast Cancer Res Treat* **112**:389–403.
- Qian S, Tong S, Wu J, Tian L, Qi Z, Chen B, Zhu D, and Zhang Y (2020) Paris saponin VII extracted from *Trillium tschonoskii* induces autophagy and apoptosis in NSCLC cells. *J Ethnopharmacol* **248**:112304.
- Ranganathan AC, Zhang L, Adam AP, and Aguirre-Ghiso JA (2006) Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. *Cancer Res* **66**:1702–1711.
- Rebecca VW and Amaravadi RK (2016) Emerging strategies to effectively target autophagy in cancer. *Oncogene* **35**:1–11.
- Ren J-H, He W-S, Nong L, Zhu Q-Y, Hu K, Zhang R-G, Huang L-L, Zhu F, and Wu G (2010) Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy. *Cancer Biother Radiopharm* **25**:75–80.
- Richmond CA, Shah MS, Deary LT, Trotter DC, Thomas H, Amburuz DM, Jiang L, Whiles BB, Rickner HD, Montgomery RK, et al. (2015) Dormant intestinal stem cells are regulated by PTEN and nutritional status. *Cell Rep* **13**:2403–2411.
- Rosenfeldt MT and Ryan KM (2009) The role of autophagy in tumour development and cancer therapy. *Expert Rev Mol Med* **11**:e36.
- Sakuma Y, Matsukuma S, Nakamura Y, Yoshihara M, Koizume S, Sekiguchi H, Saito H, Nakayama H, Kameda Y, Yokose T, et al. (2013) Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells. *Lab Invest* **93**:1137–1146.
- Samaddar JS, Gaddy VT, Duplantier J, Thandavan SP, Shah M, Smith MJ, Browning D, Rawson J, Smith SB, Barrett JT, et al. (2008) A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. *Mol Cancer Ther* **7**:2977–2987.
- Sarkar A, Ghosh M, and Sil PC (2014) Nanotoxicity: oxidative stress mediated toxicity of metal and metal oxide nanoparticles. *J Nanosci Nanotechnol* **14**:730–743.
- Schmitt MJ, Philippidou D, Reinsbach SE, Margue C, Wienecke-Baldacchino A, Nashan D, Behrmann I, and Kreis S (2012) Interferon- $\gamma$ -induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells. *Cell Commun Signal* **10**:41.
- Scott SV, Nice 3rd DC, Nau JJ, Weisman LS, Kamada Y, Keizer-Gunnink I, Funakoshi T, Veenhuis M, Ohsumi Y, and Klionsky DJ (2000) Apg13p and Vac8p are part of a complex of phosphoproteins that are required for cytoplasm to vacuole targeting. *J Biol Chem* **275**:25840–25849.
- Seleverstov O, Zabirnyk O, Zscharnack M, Bulavina L, Nowicki M, Heinrich J-M, Yezhelyev M, Emmrich F, O'Regan R, and Bader A (2006) Quantum dots for human mesenchymal stem cells labeling. A size-dependent autophagy activation. *Nano Lett* **6**:2826–2832.
- Setyawati MI, Tay CY, Chia SL, Goh SL, Fang W, Neo MJ, Chong HC, Tan SM, Loo SCJ, Ng KW, et al. (2013a) Titanium dioxide nanomaterials cause endothelial cell leakiness by disrupting the homophilic interaction of VE-cadherin. *Nat Commun* **4**:1673.
- Setyawati MI, Tay CY, and Leong DT (2013b) Effect of zinc oxide nanomaterials-induced oxidative stress on the p53 pathway. *Biomaterials* **34**:10133–10142.
- Shen J, Zheng H, Ruan J, Fang W, Li A, Tian G, Niu X, Luo S, and Zhao P (2013) Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma. *Br J Cancer* **109**:164–171.
- Shen S, Kepp O, and Kroemer G (2012) *The end of autophagic cell death?* Taylor & Francis **8**(1):1–3.
- Shi C, Zhang Z, Shi J, Wang F, and Luan Y (2015) Co-delivery of docetaxel and chloroquine via PEO-PPO-PCL/TPGS micelles for overcoming multidrug resistance. *Int J Pharm* **495**:932–939.
- Shi Y-H, Ding Z-B, Zhou J, Hui B, Shi G-M, Ke A-W, Wang X-Y, Dai Z, Peng Y-F, Gu C-Y, et al. (2011) Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. *Autophagy* **7**:1159–1172.
- Shin SW, Kim SY, and Park J-W (2012) Autophagy inhibition enhances ursolic acid-induced apoptosis in PC3 cells. *Biochim Biophys Acta* **1823**:451–457.
- Shintani T, Mizushima N, Ogawa Y, Matsuura A, Noda T, and Ohsumi Y (1999) Apg10p, a novel protein-conjugating enzyme essential for autophagy in yeast. *EMBO J* **18**:5234–5241.
- Shirvalilou S, Khoei S, Khoei S, Mahdavi SR, Raoufi NJ, Motevalian M, and Karimi MY (2020) Enhancement radiation-induced apoptosis in C6 glioma tumor-bearing rats via pH-responsive magnetic graphene oxide nanocarrier. *J Photochem Photobiol B* **205**:111827.
- Simon H-U, Friis R, Tait SW, and Ryan KM (2017) Retrograde signaling from autophagy modulates stress responses. *Sci Signal* **10**:eaag2791.
- Simonsen A and Tooz SA (2009) Coordination of membrane events during autophagy by multiple class III PI3-kinase complexes. *J Cell Biol* **186**:773–782.
- Singh SS, Vats S, Chia AY-Q, Tan TZ, Deng S, Ong MS, Arfuso F, Yap CT, Goh BC, Sethi G, et al. (2018) Dual role of autophagy in hallmarks of cancer. *Oncogene* **37**:1142–1158.
- Sirichanchuen B, Pengsuparp T, and Chanvorachote P (2012) Long-term cisplatin exposure impairs autophagy and causes cisplatin resistance in human lung cancer cells. *Mol Cell Biochem* **364**:11–18.
- Skuland T, Øvrevik J, Låg M, Schwarze P, and Refsnes M (2014) Silica nanoparticles induce cytokine responses in lung epithelial cells through activation of a p38/TACE/TGF- $\alpha$ /EGFR-pathway and NF- $\kappa$ B signalling. *Toxicol Appl Pharmacol* **279**:76–86.
- Smith AG and Macleod KF (2019) Autophagy, cancer stem cells and drug resistance. *J Pathol* **247**:708–718.
- Song P, Ye L, Fan J, Li Y, Zeng X, Wang Z, Wang S, Zhang G, Yang P, Cao Z, et al. (2015) Asparaginase induces apoptosis and cytoprotective autophagy in chronic myeloid leukemia cells. *Oncotarget* **6**:3861–3873.
- Stern ST, Zolnik BS, McLeland CB, Clogston J, Zheng J, and McNeil SE (2008) Induction of autophagy in porcine kidney cells by quantum dots: a common cellular response to nanomaterials? *Toxicol Sci* **106**:140–152.
- Su J, Xu Y, Zhou L, Yu HM, Kang JS, Liu N, Quan CS, and Sun LK (2013) Suppression of chloride channel 3 expression facilitates sensitivity of human glioma U251 cells to cisplatin through concomitant inhibition of Akt and autophagy. *Anat Rec (Hoboken)* **296**:595–603.
- Su Z, Yang Z, Xu Y, Chen Y, and Yu Q (2015) Apoptosis, autophagy, necroptosis, and cancer metastasis. *Mol Cancer* **14**:48.
- Sueda T, Sakai D, Kawamoto K, Konno M, Nishida N, Koseki J, Colvin H, Takahashi H, Haraguchi N, Nishimura J, et al. (2016) BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells. *Sci Rep* **6**:18949.
- Sun K, Deng W, Zhang S, Cai N, Jiao S, Song J, and Wei L (2013) Paradoxical roles of autophagy in different stages of tumorigenesis: protector for normal or cancer cells. *Cell Biosci* **3**:35.
- Sun R, Shen S, Zhang Y-J, Xu C-F, Cao Z-T, Wen L-P, and Wang J (2016) Nanoparticle-facilitated autophagy inhibition promotes the efficacy of chemotherapeutics against breast cancer stem cells. *Biomaterials* **103**:44–55.
- Sun T, Zhang YS, Pang B, Hyun DC, Yang M, and Xia Y (2014) Engineered nanoparticles for drug delivery in cancer therapy. *Angew Chem Int Ed Engl* **53**:12320–12364.
- Sun W-L, Chen J, Wang Y-P, and Zheng H (2011a) Autophagy protects breast cancer cells from epirubicin-induced apoptosis and facilitates epirubicin-resistance development. *Autophagy* **7**:1035–1044.
- Sun Y, Liu JH, Sui YX, Jin L, Yang Y, Lin SM, and Shi H (2011b) Beclin1 overexpression inhibits proliferation, invasion and migration of CaSki cervical cancer cells. *Asian Pac J Cancer Prev* **12**:1269–1273.

- Tang F, Hu P, Yang Z, Xue C, Gong J, Sun S, Shi L, Zhang S, Li Z, Yang C, et al. (2017) SBI0206965, a novel inhibitor of Ulk1, suppresses non-small cell lung cancer cell growth by modulating both autophagy and apoptosis pathways. *Oncol Rep* **37**:3449–3458.
- Tay CY, Fang W, Setyawati MI, Sum CP, Xie J, Ng KW, Chen X, Hong CHL, and Leong DT (2013) Reciprocal response of human oral epithelial cells to internalized silica nanoparticles. *Part Part Syst Charact* **30**:784–793.
- Tekedereli I, Alpay SN, Tavares CD, Cobanoglu ZE, Kaoud TS, Sahin I, Sood AK, Lopez-Berestein G, Dalby KN, and Ozpolat B (2012) Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. *PLoS One* **7**:e41171.
- Tiram G, Segal E, Krivitsky A, Shreberk-Hassidim R, Ferber S, Ofek P, Udagawa T, Edry L, Shomron N, Roniger M, et al. (2016) Identification of dormancy-associated microRNAs for the design of osteosarcoma-targeted dendritic polyglycerol nanopolyplexes. *ACS Nano* **10**:2028–2045.
- Tong L, Yi L, Liu P, Abeysekera IR, Hai L, Li T, Tao Z, Ma H, Xie Y, Huang Y, et al. (2018) Tumour cell dormancy as a contributor to the reduced survival of GBM patients who received standard therapy. *Oncol Rep* **40**:463–471.
- Tong Y, Liu YY, You LS, and Qian WB (2012) Perifosine induces protective autophagy and upregulation of ATG5 in human chronic myelogenous leukemia cells in vitro. *Acta Pharmacol Sin* **33**:542–550.
- Vazquez-Martin A, Oliveras-Ferreras C, and Menendez JA (2009) Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. *PLoS One* **4**:e6251.
- Vega-Rubin-de-Celis S, Zou Z, Fernández AF, Ci B, Kim M, Xiao G, Xie Y, and Levine B (2018) Increased autophagy blocks HER2-mediated breast tumorigenesis. *Proc Natl Acad Sci USA* **115**:4176–4181.
- Vera-Ramirez L, Vodnala SK, Nini R, Hunter KW, and Green JE (2018) Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence. *Nat Commun* **9**:1944.
- Verfaillie T, Salazar M, Velasco G, and Agostinis P (2010) Linking ER stress to autophagy: potential implications for cancer therapy. *Int J Cell Biol* **2010**:930509.
- Wan HY, Chen JL, Zhu X, Liu L, Wang J, and Zhu XM (2017) Titania-coated gold nano-bipyramids for blocking autophagy flux and sensitizing cancer cells to proteasome inhibitor-induced death. *Adv Sci (Weinh)* **5**:1700585.
- Wang H and He X (2018) *Nanoparticles for targeted drug delivery to cancer stem cells and tumor*. *Target Drug Deliv* **1831**: pp 59–67, Springer.
- Wang J and Wu GS (2014) Role of autophagy in cisplatin resistance in ovarian cancer cells. *J Biol Chem* **289**:17163–17173.
- Wang L, Yu C, Lu Y, He P, Guo J, Zhang C, Song Q, Ma D, Shi T, and Chen Y (2007a) TMEM166, a novel transmembrane protein, regulates cell autophagy and apoptosis. *Apoptosis* **12**:1489–1502.
- Wang S-M, Li X-H, and Xiu Z-L (2014a) Over-expression of Beclin-1 facilitates acquired resistance to histone deacetylase inhibitor-induced apoptosis. *Asian Pac J Cancer Prev* **15**:7913–7917.
- Wang Y, Lin YX, Qiao ZY, An HW, Qiao SL, Wang L, Rajapaksha RP, and Wang H (2015a) Self-assembled autophagy-inducing polymeric nanoparticles for breast cancer interference in-vivo. *Adv Mater* **27**:2627–2634.
- Wang ZH, Xu L, Duan ZL, Zeng LQ, Yan NH, and Peng ZL (2007b) Beclin 1-mediated macroautophagy involves regulation of caspase-9 expression in cervical cancer HeLa cells. *Gynecol Oncol* **107**:107–113.
- Wang Z, Wang N, Liu P, Chen Q, Situ H, Xie T, Zhang J, Peng C, Lin Y, and Chen J (2014b) MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin. *Oncotarget* **5**:7013–7026.
- Wang Z, Zhu S, Zhang G, and Liu S (2015b) Inhibition of autophagy enhances the anticancer activity of bortezomib in B-cell acute lymphoblastic leukemia cells. *Am J Cancer Res* **5**:639–650.
- Warheit DB (2010) Debunking some misconceptions about nanotoxicology. *Nano Lett* **10**:4777–4782.
- Warr MR, Binnewies M, Flach J, Reynaud D, Garg T, Malhotra R, Debnath J, and Passequé E (2013) FOXO3A directs a protective autophagy program in haematopoietic stem cells. *Nature* **494**:323–327.
- Washington MN, Suh G, Orozco AF, Sutton MN, Yang H, Wang Y, Mao W, Millward S, Ornelas A, Atkinson N, et al. (2015) ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts. *Cell Death Dis* **6**:e1836.
- Wei M and Le W-D (2019) *The role of nanomaterials in autophagy*. *Autophagy Biol and Dis* **1206**: pp 273–286, Springer.
- Wei P, Zhang L, Lu Y, Man N, and Wen L (2010) C60(Nd) nanoparticles enhance chemotherapeutic susceptibility of cancer cells by modulation of autophagy. *Nanotechnology* **21**:495101.
- Wen J, Yeo S, Wang C, Chen S, Sun S, Haas MA, Tu W, Jin F, and Guan J-L (2015) Autophagy inhibition re-sensitizes pulse stimulation-selected paclitaxel-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis. *Breast Cancer Res Treat* **149**:619–629.
- White E and DiPaola RS (2009) The double-edged sword of autophagy modulation in cancer. *Clin Cancer Res* **15**:5308–5316.
- Wu H-M, Jiang Z-F, Ding P-S, Shao L-J, and Liu R-Y (2015) Hypoxia-induced autophagy mediates cisplatin resistance in lung cancer cells. *Sci Rep* **5**:12291.
- Wu L, Zhang Y, Zhang C, Cui X, Zhai S, Liu Y, Li C, Zhu H, Qu G, Jiang G, et al. (2014) Tuning cell autophagy by diversifying carbon nanotube surface chemistry. *ACS Nano* **8**:2087–2099.
- Wu WK, Coffelt SB, Cho CH, Wang XJ, Lee CW, Chan FK, Yu J, and Sung JJ (2012) The autophagic paradox in cancer therapy. *Oncogene* **31**:939–953.
- Wu X, Liang L, Dong L, Yu Z, and Fu X (2013) Effect of ARHI on lung cancer cell proliferation, apoptosis and invasion in vitro. *Mol Biol Rep* **40**:2671–2678.
- Xie C-M, Chan WY, Yu S, Zhao J, and Cheng CH (2011) Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation. *Free Radic Biol Med* **51**:1365–1375.
- Xie W, Zhang L, Jiao H, Guan L, Zha J, Li X, Wu M, Wang Z, Han J, and You H (2015) Chaperone-mediated autophagy prevents apoptosis by degrading BBC3/PUMA. *Autophagy* **11**:1623–1635.
- Xu L, Liu J-H, Zhang J, Zhang N, and Wang Z-H (2015) Blockade of autophagy aggravates endoplasmic reticulum stress and improves Paclitaxel cytotoxicity in human cervical cancer cells. *Cancer Res Treat* **47**:313–321.
- Yang M-C, Wang H-C, Hou Y-C, Tung H-L, Chiu T-J, and Shan Y-S (2015) Blockade of autophagy reduces pancreatic cancer stem cell activity and potentiates the tumoricidal effect of gemcitabine. *Mol Cancer* **14**:179.
- Yang X, Niu B, Wang L, Chen M, Kang X, Wang L, Ji Y, and Zhong J (2016) Autophagy inhibition enhances colorectal cancer apoptosis induced by dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BE225. *Oncol Lett* **12**:102–106.
- Yin Z, Pascual C, and Klionsky DJ (2016) Autophagy: machinery and regulation. *Microb Cell* **3**:588–596.
- You Y-H, Lin Y-F, Nirosha B, Chang H-T, and Huang Y-F (2019) Polydopamine-coated gold nanostar for combined antitumor and antiangiogenic therapy in multi-drug-resistant breast cancer. *Nanotheranostics* **3**:266–283.
- Yu L, Gu C, Zhong D, Shi L, Kong Y, Zhou Z, and Liu S (2014a) Induction of autophagy counteracts the anticancer effect of cisplatin in human esophageal cancer cells with acquired drug resistance. *Cancer Lett* **355**:34–45.
- Yu L, Lu Y, Man N, Yu SH, and Wen LP (2009) Rare earth oxide nanocrystals induce autophagy in HeLa cells. *Small* **5**:2784–2787.
- Yu S-H, Kao Y-T, Wu J-Y, Huang S-H, Huang S-T, Lee C-M, Cheng K-T, and Lin C-M (2011) Inhibition of AMPK-associated autophagy enhances caffeic acid phenethyl ester-induced cell death in C6 glioma cells. *Planta Med* **77**:907–914.
- Yu Y, Duan J, Yu Y, Li Y, Liu X, Zhou X, Ho KF, Tian L, and Sun Z (2014b) Silica nanoparticles induce autophagy and autophagic cell death in HepG2 cells triggered by reactive oxygen species. *J Hazard Mater* **270**:176–186.
- Yuan G, Yan S-F, Xue H, Zhang P, Sun J-T, and Li G (2014) Cucurbitacin I induces protective autophagy in glioblastoma in vitro and in vivo. *J Biol Chem* **289**:10607–10619.
- Zhang C, Jiang Y, Zhang J, Huang J, and Wang J (2015) 8-p-Hydroxybenzoyl tovarol induces paraptosis like cell death and protective autophagy in human cervical cancer HeLa cells. *Int J Mol Sci* **16**:14979–14996.
- Zhang H, Lei Y, Yuan P, Li L, Luo C, Gao R, Tian J, Feng Z, Nice EC, and Sun J (2014a) ROS-mediated autophagy induced by dysregulation of lipid metabolism plays a protective role in colorectal cancer cells treated with gambogic acid. *PLoS One* **9**:e96418.
- Zhang LH, Yang AJ, Wang M, Liu W, Wang CY, Xie XF, Chen X, Dong JF, and Li M (2016) Enhanced autophagy reveals vulnerability of P-gp mediated epirubicin resistance in triple negative breast cancer cells. *Apoptosis* **21**:473–488.
- Zhang L, Fu L, Zhang S, Zhang J, Zhao Y, Zheng Y, He G, Yang S, Ouyang L, and Liu B (2017a) Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo. *Chem Sci (Camb)* **8**:2687–2701.
- Zhang M, Kim HS, Jin T, and Moon WK (2017b) Near-infrared photothermal therapy using EGFR-targeted gold nanoparticles increases autophagic cell death in breast cancer. *J Photochem Photobiol B* **170**:58–64.
- Zhang N, Qi Y, Wadham C, Wang L, Warren A, Di W, and Xia P (2010a) FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: a protective role of autophagy. *Autophagy* **6**:1157–1167.
- Zhang Q, Yang W, Man N, Zheng F, Shen Y, Sun K, Li Y, and Wen L-P (2009) Autophagy-mediated chemosensitization in cancer cells by fullerene C60 nanocrystal. *Autophagy* **5**:1107–1117.
- Zhang X, Dong Y, Zeng X, Liang X, Li X, Tao W, Chen H, Jiang Y, Mei L, and Feng S-S (2014b) The effect of autophagy inhibitors on drug delivery using biodegradable polymer nanoparticles in cancer treatment. *Biomaterials* **35**:1932–1943.
- Zhang Y, Sha R, Zhang L, Zhang W, Jin P, Xu W, Ding J, Lin J, Qian J, Yao G, et al. (2018) Harnessing copper-palladium alloy tetrapod nanoparticle-induced pro-survival autophagy for optimized photothermal therapy of drug-resistant cancer. *Nat Commun* **9**:4236.
- Zhang Y, Yu C, Huang G, Wang C, and Wen L (2010b) Nano rare-earth oxides induced size-dependent vacuolization: an independent pathway from autophagy. *Int J Nanomedicine* **5**:601–609.
- Zhang Y, Zhang L, Gao J, and Wen L (2019) Pro-death or pro-survival: contrasting paradigms on nanomaterial-induced autophagy and exploitations for cancer therapy. *Acc Chem Res* **52**:3164–3176.
- Zheng W, Wei M, Li S, and Le W (2016) Nanomaterial-modulated autophagy: underlying mechanisms and functional consequences. *Nanomedicine (Lond)* **11**:1417–1430.
- Zhou W, Miao Y, Zhang Y, Liu L, Lin J, Yang JY, Xie Y, and Wen L (2013) Induction of cyto-protective autophagy by paramonitroiseite VO2 nanocrystals. *Nanotechnology* **24**:165102.

**Address correspondence to:** Roghayeh Sheervalilou, Assistant prof. of Molecular Medicine, Pharmacology Research Center, Zahedan University of Medical Sciences, Dr. Hesabi Street, Zahedan, Iran. ORCID: 0000-0001-7996-845X. Phone No: +985433295705, Fax: +985433295705, Postal code: 9816743463. E-mail: sheervalilou@tbzmed.ac.ir